{"study_id": 76316, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC), alone or in combination with ascorbic acid, could prevent contrast-induced nephropathy (CIN) in high-risk patients compared to standard hydration alone.", "results_summary": "The study found no significant benefit of NAC, ascorbic acid, or their combination over standard hydration in preventing CIN, with no statistically significant differences in creatinine-related outcomes between the groups.", "population_specificity": "Patients undergoing coronary angiography or percutaneous coronary intervention with serum creatinine \u2265 1.3 mg/dL or on diabetes medication.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Creatinine was measured 4-5 days post-procedure, but intervention duration is not detailed.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:55.161600+00:00"}
{"study_id": 76317, "supplement_id": 1364, "safety_score": "30", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to assess the clinical effectiveness and safety of intravenous N-acetylcysteine for treating patients with systemic inflammatory response syndrome (SIRS) or sepsis.", "results_summary": "N-acetylcysteine showed no significant effect on mortality, length of stay, duration of mechanical ventilation, or incidence of new organ failure. Late application (after 24 hours of symptoms) was associated with cardiovascular instability, suggesting potential harm.", "population_specificity": "Patients with SIRS or sepsis.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:57.912233+00:00"}
{"study_id": 76319, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine could normalize deficits caused by glutathione deficiency in rodent models and improve symptoms of schizophrenia and bipolar disorder when used as an adjunct to antipsychotic medication.", "results_summary": "N-Acetylcysteine normalized some behavioral and neurochemical deficits in GSH-deficient mice and improved symptoms in schizophrenia and bipolar disorder patients when combined with antipsychotics. The study suggests redox regulation as a potential therapeutic target.", "population_specificity": "Rodent models with GSH deficit and human patients with schizophrenia or bipolar disorder.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:57.995095+00:00"}
{"study_id": 76318, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to assess whether N-Acetylcysteine (NAC), combined with specific probiotics, could reduce bacterial overgrowth in long-term PPI users and partially restore the gastric barrier effect.", "results_summary": "NAC, administered with probiotics, significantly reduced bacterial overgrowth in long-term PPI-treated subjects, restoring the gastric barrier effect and decreasing harmful fecal bacteria.", "population_specificity": "30 subjects treated with PPIs (short-term: 3-12 months; long-term: >12 months) and 10 control subjects not taking PPIs.", "effective_dosage": "60 mg (included in the probiotic formulation).", "study_duration": "10 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:58.207795+00:00"}
{"study_id": 76322, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 60, "study_goal": "The researchers aimed to evaluate the potential role of N-Acetylcysteine as an adjunctive therapy for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).", "results_summary": "The abstract suggests that N-Acetylcysteine shows promise in treating SJS/TEN, but further studies are needed to confirm its benefits. No specific efficacy data or adverse effects are reported.", "population_specificity": "Patients with Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:00.948472+00:00"}
{"study_id": 76320, "supplement_id": 1364, "safety_score": "100", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine if oral N-Acetylcysteine (NAC) increases intraplatelet glutathione (GSH) levels and reduces platelet-monocyte conjugation in patients with type 2 diabetes.", "results_summary": "Oral NAC reduced platelet-monocyte conjugation within 2 hours, with effects sustained after 7 days. It also raised intraplatelet GSH in individuals with depleted levels and showed a negative correlation between baseline GSH and platelet-monocyte conjugation, with no adverse events reported.", "population_specificity": "Men or post-menopausal women with well-controlled type 2 diabetes (HbA1c < 10%), not on aspirin or statins (n = 14, age 43-79).", "effective_dosage": "1,200 mg once daily.", "study_duration": "7 days per study arm (crossover design).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:01.143657+00:00"}
{"study_id": 76321, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC) improves 1-year survival and liver transplantation-free survival in children with non-acetaminophen acute liver failure (non-APAP PALF).", "results_summary": "NAC did not improve 1-year survival in non-APAP PALF and was associated with significantly lower 1-year liver transplantation-free survival, particularly in children under 2 years old. No significant differences were observed in ICU/hospital stays, organ failure, or hepatic encephalopathy scores between NAC and placebo groups.", "population_specificity": "Children from birth to age 17 with non-acetaminophen acute liver failure (non-APAP PALF).", "effective_dosage": "150 mg/kg/day via continuous intravenous infusion.", "study_duration": "Up to 7 days.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:02.356259+00:00"}
{"study_id": 76323, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the frequency of complications, treatments (including antidotes like N-Acetylcysteine), and outcomes in patients with acute poisoning.", "results_summary": "N-Acetylcysteine was used as an antidote in 11% of cases, with 5% of recipients developing allergic reactions, most of which were mild; only one case required discontinuation of treatment. The study noted an increase in complications over five years but few permanent sequelae.", "population_specificity": "Adults (\u226516 years) admitted to hospitals in Oslo for acute poisoning.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:03.785876+00:00"}
{"study_id": 76324, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine the effect of oral N-acetylcysteine (NAC) on plasma levels of inflammatory markers in Continuous Ambulatory Peritoneal Dialysis (CAPD) patients.", "results_summary": "Short-term oral NAC treatment significantly reduced levels of inflammatory markers (PCT, IL-6, IL-1, C3, sICAM, hsCRP, and TNF-) compared to the control group. The results were statistically significant across all measured parameters.", "population_specificity": "32 patients on regular CAPD, divided into two matched groups of 16.", "effective_dosage": "600 mg twice daily (total 1200 mg/day).", "study_duration": "8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:04.886896+00:00"}
{"study_id": 76326, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to evaluate whether N-Acetylcysteine (NAC) could mitigate aminoglycoside-induced ototoxicity in dialysis patients.", "results_summary": "The study found that NAC, as an effective antioxidant, shows promise in reducing aminoglycoside ototoxicity in dialysis patients, with clinical and experimental data supporting its recommendation for this population.", "population_specificity": "Dialysis patients receiving aminoglycoside antibiotics.", "effective_dosage": "Not Assessed", "study_duration": "Not Assessed", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:06.409482+00:00"}
{"study_id": 76325, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine whether N-acetylcysteine (NAC) could suppress TNF\u03b1-induced sPLA2-V expression and prevent proatherogenic changes in LDL.", "results_summary": "NAC reduced TNF\u03b1-induced sPLA2-V mRNA and protein levels in HUVEC and prevented the enhancement of LPC content in LDL and monocyte chemoattractant protein-1 mRNA.", "population_specificity": "Human umbilical vein endothelial cells (HUVEC) and hypertensive type 2 diabetic patients (for telmisartan, not NAC).", "effective_dosage": "20 mM NAC (administered before and during TNF\u03b1 stimulation).", "study_duration": "Not specified for NAC (study duration for telmisartan was 2 months).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:07.752545+00:00"}
{"study_id": 76328, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine could effectively modulate oxidative stress markers in experimental models of minimally invasive surgery.", "results_summary": "N-Acetylcysteine was found to reduce oxidative stress markers in experimental models, though it did not fully prevent oxidative stress as mesna did. The results were consistent with other agents except pentoxifylline, which showed contrasting effects.", "population_specificity": "Rats or rabbits subjected to pneumoperitoneum or pneumoretroperitoneum (not full surgical operations).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:09.487267+00:00"}
{"study_id": 76330, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine if N-Acetylcysteine could disrupt H. pylori biofilm and improve eradication rates when combined with antibiotics.", "results_summary": "N-Acetylcysteine treatment prior to antibiotic therapy led to the disappearance of gastric biofilm in all patients where H. pylori was eradicated, suggesting its effectiveness in breaking down biofilm barriers.", "population_specificity": "Patients with H. pylori infections.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:11.062475+00:00"}
{"study_id": 76329, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the effectiveness of RenalGuard therapy (hydration with saline and NAC) versus sodium bicarbonate solution and NAC in preventing contrast-induced acute kidney injury (CI-AKI) in high-risk patients.", "results_summary": "The RenalGuard group (hydration with saline and NAC) showed a lower incidence of CI-AKI (11%) compared to the Control group (20.5%), with statistically significant differences in serum creatinine and CyC levels, suggesting NAC's role in reducing kidney injury.", "population_specificity": "High-risk patients with an estimated glomerular filtration rate (eGFR) \u226430 mL/min/1.73 m\u00b2 and/or a risk score \u226511.", "effective_dosage": "Not specified", "study_duration": "48 hours post-procedure", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:11.078597+00:00"}
{"study_id": 76331, "supplement_id": 1364, "safety_score": "20", "efficacy_score": 10, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the safety and efficacy of a three-drug regimen (prednisone, azathioprine, and N-acetylcysteine) compared to NAC alone or placebo in treating idiopathic pulmonary fibrosis.", "results_summary": "The combination therapy group showed significantly increased rates of death and hospitalization compared to placebo, with no evidence of physiological or clinical benefit. The study did not report results for the NAC-only group.", "population_specificity": "Patients with idiopathic pulmonary fibrosis and mild-to-moderate lung-function impairment.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Mean follow-up of 32 weeks (planned 60-week treatment period).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:12.876343+00:00"}
{"study_id": 76332, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 50, "study_goal": "The researchers aimed to evaluate the effectiveness of N-Acetylcysteine as part of a treatment regimen for Amanita mushroom poisoning.", "results_summary": "The study reported successful treatment of two patients with Amanita mushroom poisoning using N-Acetylcysteine alongside other therapies, suggesting potential efficacy in this context.", "population_specificity": "Two patients in the northeastern United States with Amanita mushroom ingestion.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:12.930682+00:00"}
{"study_id": 76334, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine if N-Acetylcysteine (NAC) could normalize glutamate levels in the dorsal anterior cingulate cortex (dACC) of cocaine-dependent patients and healthy controls, and its relation to impulsivity.", "results_summary": "NAC reduced elevated glutamate levels in cocaine-dependent patients but had no effect in healthy controls. Higher baseline glutamate levels and impulsivity predicted greater NAC-induced glutamate reduction, suggesting NAC may normalize glutamatergic abnormalities in addiction.", "population_specificity": "8 cocaine-dependent patients and 14 healthy controls", "effective_dosage": "2400 mg (single dose)", "study_duration": "Single administration", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:15.982433+00:00"}
{"study_id": 76335, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine could restore IL-12 and IFN-\u03b3 production and improve bacterial killing in diabetic patients with glutathione deficiency.", "results_summary": "N-Acetylcysteine selectively restored IL-12 and IFN-\u03b3 production in diabetic PBMCs and improved bacterial killing, suggesting a potential therapeutic role in mitigating susceptibility to intracellular bacterial infections like melioidosis.", "population_specificity": "Diabetic patients with impaired immune responses to bacterial infections.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:16.935534+00:00"}
{"study_id": 76333, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to examine the safety, tolerance, and efficacy of N-acetylcysteine (NAC) in improving lupus disease activity by modulating T cell dysfunction via mitochondrial transmembrane potential and mTOR inhibition.", "results_summary": "NAC at 2.4 gm and 4.8 gm doses significantly reduced disease activity scores (SLEDAI, BILAG, FAS), improved mitochondrial function, reduced mTOR activity, enhanced apoptosis, and modulated T cell subsets, though 4.8 gm caused reversible nausea in 33% of patients.", "population_specificity": "36 systemic lupus erythematosus (SLE) patients, with 42 healthy controls matched for age, sex, and ethnicity.", "effective_dosage": "1.2 gm, 2.4 gm, or 4.8 gm daily.", "study_duration": "3-month treatment period with follow-up assessments.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:17.136950+00:00"}
{"study_id": 76327, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 75, "quality_score": 90, "study_goal": "The researchers aimed to investigate whether N-Acetylcysteine (NAC) could effectively treat cannabis dependence in adolescents, complementing psychosocial interventions.", "results_summary": "Participants receiving NAC had 2.4 times higher odds of negative urine cannabinoid tests compared to placebo, indicating significant efficacy. NAC was well tolerated with minimal adverse events.", "population_specificity": "Cannabis-dependent adolescents aged 15-21 years (N=116).", "effective_dosage": "1200 mg twice daily.", "study_duration": "8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:19.212131+00:00"}
{"study_id": 76336, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate whether N-Acetylcysteine (NAC) improves residual renal function (RRF) in chronic hemodialysis patients.", "results_summary": "NAC administration significantly improved RRF, increasing urine volume, residual renal Kt/V, and residual GFR in chronic hemodialysis patients. The improvements were statistically significant (P < 0.01) across all measured parameters.", "population_specificity": "Chronic hemodialysis patients with residual urine output of at least 100 mL/24 hours.", "effective_dosage": "1200 mg twice daily", "study_duration": "2 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:19.548938+00:00"}
{"study_id": 76337, "supplement_id": 1364, "safety_score": "90", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate whether oral N-acetylcysteine (NAC) as an adjuvant to clomiphene citrate (CC) improves ovulation and pregnancy outcomes in infertile patients with polycystic ovary syndrome (PCOS).", "results_summary": "The study found that NAC significantly increased the number of follicles >18 mm, endometrial thickness, ovulation rates, and pregnancy rates compared to placebo, with no reported adverse effects or cases of ovarian hyperstimulation syndrome.", "population_specificity": "Infertile patients with polycystic ovary syndrome (PCOS).", "effective_dosage": "1.2 g/d of NAC plus 100 mg/d of CC for 5 days starting at day 3 of the menstrual cycle.", "study_duration": "5 days per menstrual cycle (timing based on hCG injection and follow-up).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:21.240576+00:00"}
{"study_id": 76338, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine, as an adjunct to saline therapy, was superior in preserving renal function in patients with chronic kidney disease undergoing contrast-assisted tomography compared to saline alone.", "results_summary": "The study found no significant difference in serum creatinine change between N-Acetylcysteine, vitamin E, and saline alone. No patient developed contrast-induced acute kidney injury, indicating no additional benefit from N-Acetylcysteine over saline.", "population_specificity": "Patients with chronic kidney disease stage 1-4 (mean age 74.6 years, 17 females, 9 diabetics, all Caucasians).", "effective_dosage": "4800 mg p.o. (total dose).", "study_duration": "24 hours.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:22.709838+00:00"}
{"study_id": 76339, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to examine the impact of adopting different treatment line nomograms (single or lower, risk-stratified) on the number of patients treated with N-Acetylcysteine for acute paracetamol poisoning in the UK.", "results_summary": "The study found that adopting a single 150 mg/L treatment line would simplify algorithms and maintain similar overall treatment numbers, while a 100 mg/L or 150/75 mg/L approach would significantly increase treatment numbers and costs. The risk of untreated high-risk cases developing significant hepatotoxicity was deemed small.", "population_specificity": "Patients with acute single-time-point paracetamol poisoning presenting to an inner-city emergency department.", "effective_dosage": "Not specified (treatment based on plasma paracetamol concentration nomograms).", "study_duration": "Not specified (retrospective analysis of cases).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:23.490060+00:00"}
{"study_id": 76340, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate whether adenosine antagonists, including theophylline with or without N-Acetylcysteine, could prevent contrast-induced acute kidney injury (AKI).", "results_summary": "Theophylline significantly reduced the risk of contrast-induced AKI and improved kidney function post-contrast exposure, but no clear effects on dialysis requirement or mortality were observed. N-Acetylcysteine's specific effects were not separately analyzed in the results.", "population_specificity": "Patients undergoing contrast procedures.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:23.692192+00:00"}
{"study_id": 76342, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to explore whether N-Acetylcysteine could help counter Type 1 hypersensitivity disorders by replenishing glutathione levels.", "results_summary": "Preliminary evidence suggests N-Acetylcysteine may help restore glutathione levels, potentially countering immune imbalances linked to environmental chemical exposure. The study highlights its possible therapeutic role in Type 1 hypersensitivity disorders.", "population_specificity": "Not specified (in vitro and in vivo animal models referenced, but human population not detailed).", "effective_dosage": "Not provided", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:25.092085+00:00"}
{"study_id": 76341, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the role of mucolytic agents, including N-Acetylcysteine, in improving mucus drainage and restoring physiological sinus conditions in acute recurrent rhinosinusitis.", "results_summary": "The study suggests that mucolytic agents like N-Acetylcysteine are commonly prescribed alongside steroids to reduce mucus viscosity and improve clearance, though their real efficacy remains controversial. The primary goal was to reduce acute episodes and delay exacerbations, potentially avoiding surgical intervention.", "population_specificity": "Patients with acute recurrent rhinosinusitis, excluding those requiring immediate surgical treatment due to anatomical obstructions.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:25.917080+00:00"}
{"study_id": 76343, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether N-acetylcysteine could suppress pro-oxidant levels and NF-\u03baB activation in myeloma cells treated with IL-6 and oxidative stress-inducing agents.", "results_summary": "N-acetylcysteine suppressed both pro-oxidant levels and NF-\u03baB activation in myeloma cells, indicating its potential role in mitigating IL-6-induced therapy resistance. The study suggests that targeting antioxidant pathways like those influenced by N-acetylcysteine could enhance myeloma cell responses to treatment.", "population_specificity": "Multiple myeloma cells (in vitro study)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:28.914964+00:00"}
{"study_id": 76345, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to examine risk factors for contrast-induced nephropathy (CIN) in high-risk patients with renal impairment undergoing PCI, despite prophylactic use of N-acetylcysteine and saline hydration.", "results_summary": "Despite routine prophylaxis with N-acetylcysteine and saline hydration, CIN occurred in 11.4% of patients, with higher incidence in those with more severe renal impairment. The study identified additional risk factors (age, anemia, hypotension, etc.) and developed a predictive model for CIN.", "population_specificity": "Patients with impaired renal function (eGFR < 60 ml/min/1.73 m\u00b2) undergoing PCI.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:30.348505+00:00"}
{"study_id": 76346, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 50, "study_goal": "The researchers aimed to explore the potential of N-acetylcysteine as a therapeutic option for preventing ifosfamide-induced Fanconi's syndrome and diabetes insipidus.", "results_summary": "Preliminary animal models suggest N-acetylcysteine may be promising when added to ifosfamide treatment, but more research is needed before clinical use. The study does not provide conclusive human efficacy data.", "population_specificity": "Adults treated with ifosfamide for recurrent sarcoma with lung metastases.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:30.917642+00:00"}
{"study_id": 76348, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine the cost-effectiveness of N-acetylcysteine compared to methionine in treating acute paracetamol poisoning in Sri Lanka.", "results_summary": "N-acetylcysteine was more effective than methionine for patients treated 10-24 hours after poisoning, with a favorable incremental cost-effectiveness ratio. Methionine was cost-effective for patients treated within 10 hours.", "population_specificity": "Patients admitted to the National Hospital of Sri Lanka with acute paracetamol overdose.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:31.647069+00:00"}
{"study_id": 76347, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the potential of N-Acetylcysteine (NAC) as a mucolytic agent and its role in managing chronic obstructive pulmonary disease (COPD) by targeting oxidative stress and inflammation.", "results_summary": "NAC was found to regulate redox status, influence mucin expression, and potentially act as a mucolytic agent by targeting oxidative stress and inflammation in COPD. The study suggests NAC may interfere with signaling pathways related to apoptosis, angiogenesis, cell growth, and inflammatory response.", "population_specificity": "Patients with chronic obstructive pulmonary disease (COPD) and other respiratory conditions involving mucus hypersecretion.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:33.793377+00:00"}
{"study_id": 76349, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to determine whether local (intrarenal) or intravenous application of N-Acetylcysteine (NAC) could prevent contrast medium-induced nephropathy (CIN) in patients undergoing primary angioplasty.", "results_summary": "The study found no significant difference in CIN rates between intravenous NAC, intrarenal NAC, and placebo groups, indicating NAC had no prophylactic effect on CIN. Ejection fraction and baseline renal function were significantly correlated with CIN occurrence.", "population_specificity": "312 patients with ST-segment elevation myocardial infarction undergoing primary angiography.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:35.578087+00:00"}
{"study_id": 76351, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the effectiveness of N-Acetylcysteine as an antioxidant in preventing contrast-induced nephropathy (CIN) in high-risk patients.", "results_summary": "The study found inconsistent data regarding the efficacy of N-Acetylcysteine in preventing CIN, with some promise but requiring further confirmation. Other measures like hydration and discontinuing nephrotoxic drugs were more consistently effective.", "population_specificity": "High-risk patients undergoing procedures involving contrast media.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:38.162795+00:00"}
{"study_id": 76344, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine has a protective effect against drug-induced liver injury (DILI) in patients taking antituberculosis medication.", "results_summary": "The study found that N-Acetylcysteine may be protective against DILI in patients on antituberculosis therapy, suggesting potential benefits in mitigating liver injury. However, the abstract does not provide detailed efficacy data or statistical significance.", "population_specificity": "Patients taking antituberculosis medication (specific demographics not detailed).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:38.589143+00:00"}
{"study_id": 76352, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to investigate the potential beneficial role of N-acetylcysteine in preventing TB drug-induced liver injury (TB DILI) and treating drug-induced acute liver failure (DIALF).", "results_summary": "The abstract mentions recent reports of N-acetylcysteine's beneficial role in DIALF and in preventing TB DILI in elderly individuals, though further investigation is needed. No specific efficacy data or statistical significance is provided.", "population_specificity": "Elderly individuals and patients with TB drug-induced liver injury or acute liver failure.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:39.230195+00:00"}
{"study_id": 76353, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to determine the effects of oral N-acetylcysteine (NAC) on oxidative stress markers, hemolysis, coagulation, endothelial activation, and tolerability in sickle cell disease (SCD) patients.", "results_summary": "NAC treatment increased whole blood glutathione levels and reduced erythrocyte phosphatidylserine exposure, advanced glycation end-products (AGEs), and cell-free hemoglobin. The supplement was generally well-tolerated, with only one patient unable to tolerate the higher dose.", "population_specificity": "Eleven sickle cell disease patients (10 homozygous HbSS, 1 HbS\u03b2(0)-thalassemia).", "effective_dosage": "1,200 mg or 2,400 mg daily.", "study_duration": "6 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:40.612556+00:00"}
{"study_id": 76354, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to assess the efficacy of inhaled N-acetylcysteine (NAC) monotherapy in Japanese patients with early-stage idiopathic pulmonary fibrosis (IPF).", "results_summary": "The study found no significant overall differences in forced vital capacity (FVC) change between NAC-treated and control groups. However, post hoc analyses suggested NAC may stabilize FVC in subsets of patients with lower baseline FVC or diffusing capacity.", "population_specificity": "Japanese patients with mild-to-moderate IPF and no exercise-induced desaturation.", "effective_dosage": "352.4 mg by inhalation twice daily.", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:40.823490+00:00"}
{"study_id": 76355, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 65, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine provides added benefit in preventing contrast-induced nephropathy in vascular surgery patients undergoing angiography.", "results_summary": "Two studies found that N-Acetylcysteine administration prior to angiography did not provide added benefit in preventing contrast-induced nephropathy. The overall frequency of contrast-induced nephropathy in vascular surgery patients was 9.2%.", "population_specificity": "Patients undergoing vascular surgery, particularly those with advanced age, pre-existing renal disease, or arterial hypertension.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:42.184805+00:00"}
{"study_id": 76356, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to examine the real-world use and clinical outcomes of N-Acetylcysteine (NAC) in preventing contrast-induced nephropathy (CIN) during percutaneous coronary interventions.", "results_summary": "The study found no significant differences in outcomes (CIN, nephropathy-requiring dialysis, or death) between patients treated with NAC and those not receiving NAC, despite its increasing use over the study period. These results were consistent across various subgroups.", "population_specificity": "Consecutive patients undergoing nonemergent percutaneous coronary intervention from 2006 to 2009 in the Blue Cross Blue Shield of Michigan Cardiovascular Consortium.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:44.889972+00:00"}
{"study_id": 76350, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to assess the feasibility of using oral N-acetylcysteine (NAC) as a treatment for behavioral disturbances in children with autism, focusing on its glutamatergic modulation and antioxidant properties.", "results_summary": "NAC was well tolerated with limited side effects and resulted in significant improvements in irritability compared to placebo, as measured by the ABC irritability subscale. The study supports NAC's potential usefulness for treating irritability in children with autistic disorder.", "population_specificity": "Children with autistic disorder (31 male, 2 female; aged 3.2-10.7 years).", "effective_dosage": "900 mg daily for 4 weeks, then 900 mg twice daily for 4 weeks, and 900 mg three times daily for 4 weeks.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:46.416250+00:00"}
{"study_id": 76358, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 60, "study_goal": "The researchers aimed to explore the anticancer properties of N-Acetylcysteine, including its role in counteracting mutagens and preventing tumor progression.", "results_summary": "The study found that N-Acetylcysteine exhibits anticancer properties by countering mutagens and inhibiting tumor progression, likely through its role in modulating cellular redox potential and glutathione synthesis.", "population_specificity": "Not specified (general cellular mechanisms discussed).", "effective_dosage": "Not provided.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:46.718743+00:00"}
{"study_id": 76359, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to determine if N-acetylcysteine could enhance homocysteine removal during dialysis, potentially reducing cardiovascular risk in chronic renal failure patients.", "results_summary": "The study suggests that N-acetylcysteine may induce an additional decrease in homocysteine levels during dialysis, offering a potential alternative to folate therapy for lowering cardiovascular risk in uremic patients. However, the abstract does not provide specific data on the magnitude or statistical significance of this effect.", "population_specificity": "Chronic renal failure and uremia patients undergoing dialysis.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:48.002658+00:00"}
{"study_id": 76357, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to determine if N-Acetylcysteine (NAC) combined with folates (MTHF) could effectively reduce plasma homocysteine levels in hemodialysis patients compared to MTHF alone.", "results_summary": "NAC combined with MTHF significantly reduced postdialysis homocysteine levels compared to MTHF alone, with 64% of patients in the NAC group achieving levels below 12 \u03bcmol/L versus 19% in the MTHF group. However, no significant difference was observed in predialysis levels between the two treatment groups.", "population_specificity": "Clinically stable chronic hemodialysis patients on dialysis for over 3 months.", "effective_dosage": "Not specified (intravenous NAC administered during 10 hemodialysis sessions).", "study_duration": "10 hemodialysis sessions.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:49.114648+00:00"}
{"study_id": 76360, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effect of add-on N-acetylcysteine (NAC) on depressive symptoms and functional outcomes in bipolar disorder during major depressive episodes.", "results_summary": "NAC showed very large effect sizes for improving depressive symptoms and functional outcomes, with 8 out of 10 NAC-treated participants responding compared to only 1 out of 7 placebo-treated participants. The results suggest adjunctive NAC may be beneficial for major depressive episodes in bipolar disorder.", "population_specificity": "Individuals with bipolar disorder experiencing major depressive episodes.", "effective_dosage": "Not specified", "study_duration": "24 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:49.492589+00:00"}
{"study_id": 76361, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to determine whether transtympanic infusions of N-Acetylcysteine could effectively prevent cisplatin-induced ototoxicity in patients.", "results_summary": "The study found that N-Acetylcysteine-treated ears showed no significant changes in auditory thresholds, while control ears exhibited significant hearing loss at 8000 Hz. The treatment was deemed feasible and effective, with acute pain being the only notable adverse effect.", "population_specificity": "Twenty cisplatin-treated patients undergoing hydration before cisplatin infusion.", "effective_dosage": "10% N-Acetylcysteine, administered transtympanically once per cisplatin cycle.", "study_duration": "Duration matched the number of cisplatin cycles (84 infusions total).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:50.751561+00:00"}
{"study_id": 76362, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the role of N-acetylcysteine in managing increased intracranial pressure (ICP) in patients with acute liver failure (ALF).", "results_summary": "The abstract suggests that N-acetylcysteine is among the therapies being re-evaluated for its role in addressing cerebral hyperemia, a contributor to increased ICP in ALF, but specific efficacy results are not detailed.", "population_specificity": "Patients with acute liver failure (ALF) and hepatic encephalopathy (HE).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:52.579397+00:00"}
{"study_id": 76363, "supplement_id": 1364, "safety_score": "70", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine the effects of acute oral N-acetylcysteine (NAC) supplementation on performance in the Yo-Yo Intermittent Recovery Test Level 1 (YIRT-L1) after repeated bouts of damaging intermittent exercise.", "results_summary": "NAC supplementation significantly preserved YIRT-L1 performance but did not prevent muscle performance deterioration in isokinetic dynamometry tests. It also led to higher plasma creatine kinase levels and mild gastrointestinal side effects compared to placebo.", "population_specificity": "12 recreationally trained men", "effective_dosage": "Not specified", "study_duration": "6 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:53.647198+00:00"}
{"study_id": 76364, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to assess whether N-Acetylcysteine improves the quality of hepatocytes isolated from steatotic donor livers for transplantation.", "results_summary": "The study found that N-Acetylcysteine enhances the quality of hepatocytes obtained from steatotic donor livers, though cryopreservation remains detrimental to metabolic function. Further refinement of cryopreservation protocols is needed.", "population_specificity": "Hepatocytes isolated from steatotic donor livers for transplantation.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:54.424894+00:00"}
{"study_id": 76365, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers aimed to determine whether combining N-acetylcysteine with prednisolone improves survival in patients with severe acute alcoholic hepatitis compared to prednisolone alone.", "results_summary": "The study found that combination therapy significantly improved 1-month survival but did not significantly improve 6-month survival, the primary outcome. Death due to hepatorenal syndrome and infections were less frequent in the combination group.", "population_specificity": "Patients with severe acute alcoholic hepatitis.", "effective_dosage": "Intravenous N-acetylcysteine on day 1 (150, 50, and 100 mg/kg in varying glucose solutions over different durations) and days 2-5 (100 mg/kg/day in 1000 ml of 5% glucose solution).", "study_duration": "5 days of N-acetylcysteine administration alongside 4 weeks of prednisolone.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:56.714788+00:00"}
{"study_id": 76367, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effectiveness of N-Acetylcysteine as a complementary treatment for bipolar depression.", "results_summary": "The study found provisional support for N-Acetylcysteine in treating bipolar depression, though evidence was based on isolated studies. The effect was noted in combination with conventional mood stabilizers and antipsychotic medications.", "population_specificity": "Individuals with bipolar disorder (specifically bipolar depression).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:56.786607+00:00"}
{"study_id": 76366, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to determine whether oral N-acetylcysteine could prevent Ara-C-induced neurotoxicity and behavioral deficits in a rat model.", "results_summary": "The study found that 14-day oral administration of N-acetylcysteine prevented Ara-C-induced behavioral deficits and cellular alterations in the adult cerebellum of rats. No significant correlation was found between NME1 promoter SNPs and survival outcomes in AML patients, but neurotoxicity risk was linked to a specific SNP genotype.", "population_specificity": "Rats (animal model) and 360 Caucasian AML patients (human study).", "effective_dosage": "Not specified for humans; animal model used 14-day oral administration.", "study_duration": "14 days (animal model).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:57.200454+00:00"}
{"study_id": 76369, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 90, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effects of N-Acetylcysteine on oxidative stress and cardiovascular disease (CVD) outcomes in hemodialysis patients.", "results_summary": "N-Acetylcysteine was the most efficacious antioxidant, with all four studies showing a decrease in oxidative stress and one trial (n=134) demonstrating reduced CVD events.", "population_specificity": "Hemodialysis (HD) patients", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:57.896516+00:00"}
{"study_id": 76368, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to assess the effects of N-acetylcysteine (NAC) on oxidative stress, inflammation, fluid requirements, multiple organ dysfunction, and vasoactive drug requirements in burn patients.", "results_summary": "NAC treatment increased antioxidant levels (GSH and PSH), reduced inflammatory markers (IL-6, IL-8, IL-10), and decreased vasopressor requirements, though it did not significantly affect MOD scores.", "population_specificity": "Burn patients (15 on NAC, 15 controls).", "effective_dosage": "Not specified.", "study_duration": "5 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:58.534278+00:00"}
{"study_id": 76370, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the role of N-acetylcysteine in mitigating reactive oxygen species (ROS)-related toxicity caused by ZnO nanorods.", "results_summary": "N-acetylcysteine was used to demonstrate that the toxicity of ZnO nanorods (ZnO-RT and ZnO-60) was linked to ROS formation, not Zn\u00b2\u207a ion release. The study found that ZnO-60, with larger particle size, induced higher cytotoxicity than ZnO-RT.", "population_specificity": "In vitro study (no human or animal subjects specified).", "effective_dosage": "Not specified", "study_duration": "24-hour treatment", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:01.334484+00:00"}
{"study_id": 76372, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to compare the clinical use, length of treatment, and hospital stay between oral and intravenous N-Acetylcysteine (NAC) in pediatric patients with acetaminophen (APAP) intoxication.", "results_summary": "The study found that IV NAC had shorter average treatment duration (23.5 hours) and hospital stay (1.6 days) compared to oral NAC (69.5 hours and 1.95 days). Most patients received recommended dosing, but three required extended therapy.", "population_specificity": "Pediatric patients aged \u226421 years with APAP overdose.", "effective_dosage": "Not specified (routes compared: IV vs. oral).", "study_duration": "IV: 17.6-54.9 hours; oral: 33-133 hours.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:05.335070+00:00"}
{"study_id": 76371, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effects of N-Acetylcysteine in preventing contrast-induced acute kidney injury (CI-AKI) and improving tissue-level perfusion in patients with ST-segment elevation acute myocardial infarction undergoing primary percutaneous coronary intervention.", "results_summary": "All patients received high-dose N-Acetylcysteine, and the study found no significant differences in CI-AKI occurrence, tissue-level reperfusion, or major adverse cardiac events between the two contrast media groups. The results suggest N-Acetylcysteine may contribute to mitigating CI-AKI risk in this context.", "population_specificity": "Patients with ST-segment elevation acute myocardial infarction undergoing primary percutaneous coronary intervention.", "effective_dosage": "High-dose (specific amount not provided in the abstract).", "study_duration": "Not explicitly stated in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:05.408444+00:00"}
{"study_id": 76373, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the role of N-Acetylcysteine as an antioxidant and anti-inflammatory agent in slowing hepatic encephalopathy progression and preventing brain edema in acute liver failure.", "results_summary": "N-Acetylcysteine demonstrated effectiveness in reducing neuroinflammation and preventing central nervous system complications in acute liver failure by acting on both peripheral and central sites. It contributed to slowing hepatic encephalopathy progression and preventing brain edema.", "population_specificity": "Patients with acute liver failure and associated neuroinflammatory complications.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:05.919608+00:00"}
{"study_id": 76375, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether oral N-acetylcysteine (NAC) could serve as a treatment option for patients with obstructive sleep apnoea syndrome (OSAS).", "results_summary": "NAC significantly improved sleep efficiency, slow wave sleep, and reduced apnea-related metrics, snoring, and oxidative stress markers compared to baseline, with no such improvements observed in the placebo group.", "population_specificity": "20 patients diagnosed with obstructive sleep apnoea syndrome (OSAS).", "effective_dosage": "Not specified", "study_duration": "30 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:05.971042+00:00"}
{"study_id": 76376, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 70, "study_goal": "The researchers aimed to evaluate whether N-Acetylcysteine, as an antioxidant, could reduce the frequency of acute exacerbations in chronic obstructive pulmonary disease (AECOPD).", "results_summary": "The study suggests that N-Acetylcysteine may reduce exacerbation frequency in COPD patients, but further investigation is needed to confirm its efficacy and optimal use. The results were noted as varying, indicating mixed evidence.", "population_specificity": "Patients with chronic obstructive pulmonary disease (COPD) experiencing acute exacerbations (AECOPDs).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:06.371506+00:00"}
{"study_id": 76377, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the effectiveness of N-Acetylcysteine as a strategy to reduce the risk of contrast-induced nephropathy (CIN).", "results_summary": "The study found that N-Acetylcysteine has variable levels of evidence for reducing CIN risk, with further randomized trials needed to confirm its efficacy.", "population_specificity": "Patients undergoing contrast-enhanced imaging studies.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:07.205847+00:00"}
{"study_id": 76378, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy of N-Acetylcysteine (NAC) as a treatment for moderate depression in individuals with bipolar disorder during an open-label phase of a clinical trial.", "results_summary": "The study found a statistically significant reduction in depression scores (BDRS) from a mean baseline of 19.7 to 11.1 after 8 weeks of NAC treatment, along with improvements in functioning and quality of life.", "population_specificity": "149 individuals with moderate depression in the context of bipolar disorder.", "effective_dosage": "1g twice daily (BID).", "study_duration": "8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:11.725702+00:00"}
{"study_id": 76382, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effectiveness of N-Acetylcysteine in combination with corticosteroids, azathioprine, and pirfenidone for treating idiopathic pulmonary fibrosis (IPF).", "results_summary": "The study found that the combination of N-Acetylcysteine with corticosteroids, azathioprine, and pirfenidone showed significant effects in treating IPF, though other new agents are under development.", "population_specificity": "Patients diagnosed with idiopathic pulmonary fibrosis (IPF).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:14.316365+00:00"}
{"study_id": 76383, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review the therapeutic potential of N-acetylcysteine in mitigating arsenic-induced oxidative damage and related diseases.", "results_summary": "N-acetylcysteine showed prophylactic activity against arsenic-mediated injuries in both in vitro and in vivo models, likely due to its modulation of cellular thiols and protection against reactive oxygen species.", "population_specificity": "Not specified (in vitro and in vivo models).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:14.338885+00:00"}
{"study_id": 76381, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to investigate whether N-Acetylcysteine (NAC) could reduce nicotine craving, withdrawal symptoms, and the rewarding effects of smoking during short-term abstinence in heavy smokers.", "results_summary": "NAC showed no significant effect on craving but a trend toward fewer withdrawal symptoms. Subjects receiving NAC rated the first cigarette after abstinence as significantly less rewarding compared to placebo.", "population_specificity": "Heavy smokers", "effective_dosage": "3,600 mg/day", "study_duration": "3.5 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:14.461851+00:00"}
{"study_id": 76379, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to assess whether high-dose N-acetylcysteine (N-ACC) could reduce contrast-induced nephropathy (CIN) defined by Cystatin C levels and influence clinical outcomes in STEMI patients undergoing primary PCI.", "results_summary": "High-dose N-ACC did not significantly reduce CIN incidence compared to placebo (74.6% vs. 70.4%, p = 0.46). The increase in Cystatin C levels was an independent predictor of major adverse cardiac events (MACE) at 6 months.", "population_specificity": "251 patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).", "effective_dosage": "2 \u00d7 1200 mg/d for 48 hours", "study_duration": "48 hours", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:14.932943+00:00"}
{"study_id": 76384, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC) could prevent ototoxicity caused by antibiotics (amikacin and vancomycin) used in treating CAPD peritonitis.", "results_summary": "NAC was found to protect against low-frequency hearing loss and improve high-frequency hearing functions in CAPD patients receiving ototoxic antibiotics, with statistically significant results compared to the control group.", "population_specificity": "60 patients with first-time CAPD peritonitis attacks.", "effective_dosage": "Not specified", "study_duration": "4 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:16.548106+00:00"}
{"study_id": 76380, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate whether N-Acetylcysteine (NAC) could mitigate oxidative stress caused by tourniquet-induced ischemia-reperfusion during arthroscopic knee surgery.", "results_summary": "NAC prevented significant changes in oxidative stress markers (MDA, SOD, GSH-Px, TAC, TOS) compared to the control group, demonstrating a protective effect against ischemia-reperfusion injury. Its efficacy was comparable to ischemic preconditioning (IPC) in reducing oxidative stress.", "population_specificity": "45 patients undergoing arthroscopic knee surgery for meniscal/chondral lesions or pathologic medial plica.", "effective_dosage": "10 mg/kg NAC dissolved in 100 mL 0.9% normal saline, administered intravenously 30 minutes before tourniquet inflation.", "study_duration": "Single dose administered preoperatively.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:16.831346+00:00"}
{"study_id": 76374, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the effectiveness of RenalGuard therapy (hydration with saline and N-acetylcysteine controlled by the RenalGuard System) versus sodium bicarbonate and N-acetylcysteine in preventing contrast-induced acute kidney injury in high-risk patients.", "results_summary": "The study found that RenalGuard therapy (including N-acetylcysteine) was superior to sodium bicarbonate and N-acetylcysteine alone, reducing the incidence of contrast-induced acute kidney injury (11% vs. 20.5%). Secondary outcomes, including changes in cystatin C and in-hospital dialysis rates, also favored the RenalGuard group.", "population_specificity": "High-risk patients with an estimated glomerular filtration rate \u226430 mL \u00b7 min(-1) \u00b7 1.73 m(-2) and/or a risk score \u226511.", "effective_dosage": "Not specified", "study_duration": "48 hours post-procedure", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:17.260819+00:00"}
{"study_id": 76385, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 85, "study_goal": "The researchers aimed to compare the incidence of contrast-induced nephropathy (CIN) between two contrast media (iodixanol and iopromide) in patients with impaired renal function, while noting the use of N-Acetylcysteine as a similar factor between groups.", "results_summary": "The study found no significant difference in CIN incidence between the iodixanol and iopromide groups, with N-Acetylcysteine use being similar in both groups but not directly analyzed for efficacy. The abstract does not report specific outcomes attributable to N-Acetylcysteine.", "population_specificity": "Patients with creatinine clearance <60 ml/min undergoing coronary angiography and/or percutaneous coronary intervention.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:21.386559+00:00"}
{"study_id": 76389, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the potential of N-Acetylcysteine as a pharmacological treatment for cocaine dependence.", "results_summary": "The study identified N-Acetylcysteine as a promising glutamatergic agent for treating cocaine dependence, though larger randomized controlled trials are needed for confirmation.", "population_specificity": "Individuals with cocaine dependence.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:22.891637+00:00"}
{"study_id": 76388, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to summarize the pharmacological mechanisms and clinical efficacy of glutamatergic medications, including N-Acetylcysteine, for treating addictive disorders.", "results_summary": "The abstract suggests that N-Acetylcysteine shows potential utility in treating drug and behavioral addictions by modulating glutamatergic transmission, but specific efficacy data are not detailed.", "population_specificity": "Individuals with drug or behavioral addictions (e.g., pathological gambling).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:23.303343+00:00"}
{"study_id": 76387, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 80, "study_goal": "The researchers aimed to compare the effectiveness of N-Acetylcysteine (NAC) in preventing contrast-induced acute kidney injury (CI-AKI) when used with intravenous normal saline or sodium bicarbonate.", "results_summary": "The study found no significant difference in CI-AKI incidence between the groups receiving NAC with normal saline or sodium bicarbonate, indicating NAC did not reduce CI-AKI in either treatment arm.", "population_specificity": "Patients with baseline renal insufficiency scheduled for catheterization procedures.", "effective_dosage": "1,200 mg oral dose given 2-12 hr preprocedure and 6-12 hr postprocedure.", "study_duration": "Administered preprocedure and postprocedure over approximately 24 hours.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:24.615698+00:00"}
{"study_id": 76391, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine could prevent central neuroinflammation and complications like encephalopathy and brain edema in liver failure.", "results_summary": "N-Acetylcysteine, along with mild hypothermia, was found to avert central neuroinflammation due to liver failure in animal models, suggesting its potential cytoprotective effects in the brain.", "population_specificity": "Animal models of ischemic or toxic liver injury.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:24.954149+00:00"}
{"study_id": 76386, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to determine whether high-dose intravenous N-Acetylcysteine (NAC) reduces the incidence of contrast-induced nephropathy (CIN) in patients with acute coronary syndromes (ACS) undergoing coronary angiography or percutaneous coronary intervention (PCI).", "results_summary": "The study found no significant difference in the incidence of CIN between the NAC group (16%) and the placebo group (13%). Additionally, changes in serum cystatin-C, a sensitive marker for renal function, did not significantly differ between the two groups.", "population_specificity": "ACS patients undergoing coronary angiography or PCI.", "effective_dosage": "1,200 mg bolus followed by 200 mg/hr for 24 hours.", "study_duration": "24 hours.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:25.199242+00:00"}
{"study_id": 76392, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the clinical benefit of N-acetylcysteine in reducing myocardial reperfusion injury by targeting reactive oxygen species (ROS).", "results_summary": "The study found that N-acetylcysteine, along with other antioxidants, did not provide indisputable clinical benefits in reducing myocardial reperfusion injury despite favorable results in animal models. The clinical approach using antioxidants was deemed inadequate due to variations in endpoints and low specificity of compounds.", "population_specificity": "Patients with myocardial ischemia undergoing reperfusion therapy.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:25.609249+00:00"}
{"study_id": 76390, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the effectiveness of N-acetylcysteine plus hydration versus hydration alone in preventing contrast-induced nephropathy (CIN) in high-risk patients undergoing coronary angiography and percutaneous coronary intervention.", "results_summary": "N-acetylcysteine combined with hydration significantly reduced the occurrence of CIN compared to hydration alone, with no cases in the N-acetylcysteine group versus 12% in the hydration group. Serum creatinine levels improved in the N-acetylcysteine group post-intervention, and creatinine clearance rates significantly increased.", "population_specificity": "High-risk patients with impaired renal function undergoing coronary angiography and percutaneous coronary intervention.", "effective_dosage": "600mg twice daily for 2 days, starting the day before the procedure.", "study_duration": "2 days (starting the day before the procedure).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:26.474822+00:00"}
{"study_id": 76393, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine if oral N-acetylcysteine reduces contrast-induced nephropathy (CIN) and improves clinical outcomes in patients undergoing primary angioplasty for acute myocardial infarction.", "results_summary": "N-acetylcysteine showed a trend toward reducing CIN incidence (5.3% vs. 13.2% in placebo), but the difference was not statistically significant (p=0.21). No significant differences in in-hospital mortality or morbidity were observed between the groups.", "population_specificity": "Patients undergoing primary angioplasty for acute myocardial infarction (n=76).", "effective_dosage": "705 mg orally before and 12, 24, 36 hours after primary angioplasty.", "study_duration": "Administered over approximately 36 hours post-procedure.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:31.185530+00:00"}
{"study_id": 76394, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effectiveness and safety of N-acetylcysteine in preventing or treating acute kidney injury in high-risk or critically ill populations.", "results_summary": "The study included N-acetylcysteine among interventions reviewed but did not provide specific efficacy or safety results for it in the abstract. The overall GRADE evaluation suggested varying levels of evidence for different interventions.", "population_specificity": "People at high risk of acute kidney injury or critically ill individuals with acute kidney injury.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:31.242874+00:00"}
{"study_id": 76397, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate how N-acetylcysteine prevents hepatocarcinogenesis associated with transaldolase deficiency and oxidative stress.", "results_summary": "N-acetylcysteine was found to prevent hepatocarcinogenesis linked to transaldolase deficiency by counteracting oxidative stress and inhibiting aldose reductase and redox-sensitive transcription factors. The study suggests potential therapeutic benefits in conditions like fatty liver and steatohepatitis.", "population_specificity": "The study focuses on metabolic pathologies, particularly transaldolase deficiency-related conditions such as fatty liver and hepatocarcinogenesis.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:33.766495+00:00"}
{"study_id": 76396, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 45, "study_goal": "The researchers aimed to evaluate the renoprotective utility of N-Acetylcysteine in reducing acute kidney injury (AKI) and other renal outcomes in adult patients undergoing cardiac surgery with cardiopulmonary bypass.", "results_summary": "The study found no significant reduction in mortality or other renal outcomes (e.g., need for renal replacement therapy, incidence of AKI, creatinine clearance) attributable to N-Acetylcysteine. The overall quality of trials assessing pharmacological renoprotective agents, including N-Acetylcysteine, was poor.", "population_specificity": "Adult patients undergoing cardiac surgery with cardiopulmonary bypass.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:33.973441+00:00"}
{"study_id": 76398, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to identify risk factors for hepatotoxicity and death in patients with repeated supratherapeutic acetaminophen ingestion treated with N-Acetylcysteine.", "results_summary": "The study found that N-Acetylcysteine was used to treat acetaminophen poisoning, with hepatotoxicity occurring in 37% of cases. Risk factors for poor outcomes included alcoholism, viral hepatitis, and elevated serum creatinine.", "population_specificity": "Patients with repeated supratherapeutic acetaminophen ingestion (119 out of 503 subjects, mean age 39.6 years, 63.9% female).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:34.211010+00:00"}
{"study_id": 76399, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the specificity of N-acetylcysteine as an antioxidant in detecting and localizing intracellular ROS under various cellular stress conditions.", "results_summary": "N-acetylcysteine was used as a control antioxidant to validate ROS detection methods, showing agreement with other antioxidants like Trolox. The study confirmed that confocal fluorescent imaging and ESR spectroscopy reliably detected ROS increases under stress conditions, but did not specifically measure N-acetylcysteine's standalone efficacy.", "population_specificity": "In vitro cell models (32D, NIH, HL-1 cells) under stress conditions (starvation, hypoxia-reoxygenation, prooxidant treatment).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:35.026919+00:00"}
{"study_id": 76395, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers aimed to compare the effectiveness of sodium bicarbonate plus N-acetylcysteine (NAC) versus sodium chloride plus NAC in preventing contrast-induced nephropathy (CIN) in diabetic patients with impaired renal function undergoing angiography or intervention.", "results_summary": "The study found no significant difference in CIN rates between the sodium bicarbonate and sodium chloride groups, both supplemented with NAC. Hemodialysis requirements and adverse outcomes (death, myocardial infarction, stroke) were also similar at 1 and 6 months.", "population_specificity": "Diabetic patients with renal disease (serum creatinine \u22651.1 mg/dl, eGFR <60 ml/min/1.73 m\u00b2) undergoing coronary or endovascular angiography or intervention.", "effective_dosage": "Oral NAC 1,200 mg twice daily for 2 days.", "study_duration": "2 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:35.066521+00:00"}
{"study_id": 76400, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to determine the prevalence of unrecognized acetaminophen toxicity in patients with indeterminate acute liver failure and assess the role of N-Acetylcysteine in these cases.", "results_summary": "The study found that 18% of indeterminate acute liver failure cases had acetaminophen-cysteine adducts, indicating unrecognized acetaminophen toxicity. N-Acetylcysteine use was limited in this group due to lack of specific diagnosis.", "population_specificity": "Patients with indeterminate acute liver failure (n=110) and known acetaminophen-induced liver failure (n=199).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:35.547640+00:00"}
{"study_id": 76401, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine if N-Acetylcysteine (NAC) could prevent Ifosfamide-induced nephrotoxicity in children by comparing systemic exposure levels between pediatric cases and a rat model.", "results_summary": "NAC showed potential to prevent Ifosfamide-induced nephrotoxicity in children, with systemic exposure levels comparable to those in pediatric acetaminophen overdose cases. Two pediatric cases demonstrated NAC's attenuation of acute renal failure when used concurrently with chemotherapy.", "population_specificity": "Pediatric patients with solid tumors and a rat model.", "effective_dosage": "Clinically approved dose schedule (specific amounts not detailed).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:40.522187+00:00"}
{"study_id": 76403, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 70, "study_goal": "The researchers aimed to evaluate whether N-Acetylcysteine, as an antioxidant, has beneficial effects in treating idiopathic pulmonary fibrosis (IPF).", "results_summary": "The abstract suggests that N-Acetylcysteine may have some beneficial effect in IPF, but large-scale studies are needed for confirmation. No specific efficacy data or adverse effects are detailed.", "population_specificity": "Elderly patients with idiopathic pulmonary fibrosis (mean age 66 years).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:41.460593+00:00"}
{"study_id": 76405, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine inhibits RA + TPA or RA + TGF-\u03b2-stimulated VEGF secretion and ROS production in human endometrial stromal cells.", "results_summary": "N-Acetylcysteine inhibited both RA + TPA and RA + TGF-\u03b2-stimulated VEGF secretion and RA-induced ROS production, suggesting it modulates redox-sensitive signaling pathways involved in VEGF regulation.", "population_specificity": "Human endometrial stromal cells", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:42.169150+00:00"}
{"study_id": 76404, "supplement_id": 1364, "safety_score": "40", "efficacy_score": 30, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the clinical role of intravenous N-acetylcysteine in preventing contrast-induced nephropathy (CIN).", "results_summary": "The study found no conclusive evidence that intravenous N-acetylcysteine is effective in preventing CIN, with higher doses showing potential benefits but significant adverse events. The pharmacodynamic and pharmacokinetic profiles of intravenous N-acetylcysteine differ from oral administration, and its effects on serum creatinine levels were not linked to improved kidney function.", "population_specificity": "Patients with various levels of kidney function and other risk factors for CIN.", "effective_dosage": "Higher than oral doses (specific amounts not detailed).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:43.067619+00:00"}
{"study_id": 76406, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to review the pathophysiology of contrast-induced acute kidney injury (CI-AKI) and evaluate the experimental and clinical data on the effects of N-acetylcysteine (NAC) in preventing CI-AKI.", "results_summary": "The study reviewed existing data suggesting NAC may prevent CI-AKI due to its antioxidant properties, but it did not present new experimental or clinical results. The abstract implies potential benefits but does not quantify efficacy.", "population_specificity": "Patients at risk of contrast-induced acute kidney injury (CI-AKI).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:43.480831+00:00"}
{"study_id": 76408, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 40, "quality_score": 65, "study_goal": "The researchers aimed to compare the effectiveness of intravenous glutathione (GSH) and oral N-acetylcysteine (NAC) in preventing contrast medium-induced renal oxidative stress during coronary angiography.", "results_summary": "NAC did not completely prevent the increase in urinary lipid hydroperoxides (LOOHs) or the decrease in serum GSH levels post-coronary angiography, unlike GSH, which abolished these effects. NAC was less effective than GSH in mitigating oxidative stress.", "population_specificity": "21 patients with reduced renal function undergoing coronary angiography.", "effective_dosage": "Not specified for NAC (only GSH dosage provided: 100 mg/min for 30 min).", "study_duration": "Single administration before coronary angiography.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:46.815090+00:00"}
{"study_id": 76410, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 60, "study_goal": "The researchers aimed to evaluate N-Acetylcysteine as an alternative treatment for preventing postoperative atrial fibrillation following cardiac surgery.", "results_summary": "The abstract mentions N-Acetylcysteine as one of several non-antiarrhythmic drugs studied for postoperative AF prophylaxis, but no specific results or efficacy data are provided.", "population_specificity": "Patients undergoing cardiac surgery.", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:48.599744+00:00"}
{"study_id": 76409, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to review the current literature on the therapeutic potential of N-Acetylcysteine (NAC) in treating psychiatric disorders, including addiction, compulsive and grooming disorders, schizophrenia, and bipolar disorder.", "results_summary": "NAC demonstrated promising results in treating various psychiatric disorders, particularly in populations where previous treatments had limited efficacy. The mechanisms of NAC likely extend beyond its role as a glutathione precursor, involving modulation of glutamatergic, neurotropic, and inflammatory pathways.", "population_specificity": "Individuals with psychiatric disorders, including addiction, compulsive and grooming disorders, schizophrenia, and bipolar disorder.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:49.277852+00:00"}
{"study_id": 76412, "supplement_id": 1364, "safety_score": "70", "efficacy_score": 40, "quality_score": 50, "study_goal": "The researchers aimed to evaluate the clinical efficacy and safety of long-term N-Acetylcysteine (NAC) inhalation monotherapy for idiopathic pulmonary fibrosis (IPF).", "results_summary": "The study found no significant difference in survival between NAC-treated and untreated IPF patients. NAC inhalation showed modest declines in lung function (%FVC and %DLco) over time, while untreated cases had mixed results. Acute exacerbation occurred in 28.6% of treated cases.", "population_specificity": "Patients diagnosed with idiopathic pulmonary fibrosis (IPF) via surgical lung biopsy.", "effective_dosage": "Not specified", "study_duration": "One year or longer (14 cases)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:51.844122+00:00"}
{"study_id": 76411, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine if prophylactic IV N-Acetylcysteine (NAC) combined with high-dose hydration was effective in preventing contrast-induced nephropathy (CIN) in patients with mild to moderate renal dysfunction undergoing coronary angiography or PCI.", "results_summary": "NAC plus high-dose hydration significantly reduced changes in serum creatinine levels and lowered CIN rates compared to high-dose hydration alone or standard hydration. High-dose hydration without NAC showed no significant benefit over standard hydration.", "population_specificity": "Patients with mild to moderate renal dysfunction (serum creatinine \u2265 1.1mg/dL or creatinine clearance \u2264 60 mL/min) undergoing coronary angiography or PCI.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:52.429470+00:00"}
{"study_id": 76413, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to determine if N-Acetylcysteine (NAC) has a protective effect on contrast-induced renal dysfunction and whether it affects oxidative stress parameters in serum and urine.", "results_summary": "The study found no significant differences in oxidative parameters (TOC, TAC, OSI) between patients who received NAC and those who did not. NAC showed no protective effect on renal function or influence on oxidative stress markers in serum or urine.", "population_specificity": "Sixty patients with coronary artery disease undergoing elective percutaneous coronary intervention (PCI), age- and gender-matched.", "effective_dosage": "600 mg intravenous NAC.", "study_duration": "Single dose administered before PCI, with measurements taken 24 hours post-procedure.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:53.113488+00:00"}
{"study_id": 76407, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine if N-Acetylcysteine (NAC) could reduce inflammation and fluid requirements in burn patients, as well as compare its effects on organ function scores and vasoactive drug use.", "results_summary": "NAC treatment significantly reduced expression of certain leukocyte surface markers (CD11a, CD18, CD97, CD49d) and lowered vasopressor requirements from day 4 onward, though fluid requirements did not differ between groups.", "population_specificity": "28 patients with burn injuries affecting >20% of body surface area.", "effective_dosage": "Not specified", "study_duration": "5 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:54.109666+00:00"}
{"study_id": 76414, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to summarize evidence on whether N-Acetylcysteine and other amino acid supplements could prevent ischemia/reperfusion injury (IRI) in liver surgery.", "results_summary": "The study found heterogenic results for N-Acetylcysteine's effects on IRI, with no clear consensus on its efficacy, though some positive impacts on microcirculation and inflammation were noted in related trials.", "population_specificity": "Patients undergoing liver surgery or transplantation, with a focus on ischemia/reperfusion injury.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:55.145223+00:00"}
{"study_id": 76415, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effects of N-Acetylcysteine on exacerbations, disability days, and lung function in patients with chronic bronchitis and COPD.", "results_summary": "N-Acetylcysteine significantly reduced exacerbations (0.05 per patient per month) and days with disability (0.56 days per patient per month), with better effects observed in patients not taking inhaled corticosteroids. It also showed a 374 mL reduction in functional residual capacity.", "population_specificity": "Patients with chronic bronchitis (21 studies) and COPD (5 studies).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:57.735307+00:00"}
{"study_id": 76416, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to examine the potential for integrating qualitative research methods with quantitative methods in early-phase drug trials, specifically for N-Acetylcysteine (NAC) in schizophrenia patients.", "results_summary": "The study replicated principal findings using qualitative methods and identified significant differences in positive and affective symptoms between NAC- and placebo-treated participants, which were not captured by quantitative rating scales. These qualitative findings later contributed to a positive trial of NAC in bipolar disorder.", "population_specificity": "Patients with DSM-IV-TR-diagnosed schizophrenia (N = 140).", "effective_dosage": "Not specified", "study_duration": "November 2002 to July 2005 (approximately 2.5 years)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:58.122472+00:00"}
{"study_id": 76402, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the experimental and clinical evidence for using N-Acetylcysteine (NAC) as a protective agent in liver ischemia-reperfusion injury during major liver surgery or transplantation.", "results_summary": "NAC showed improvement in experimental liver I/R injury, primarily reducing transaminase levels and improving bile production in isolated perfused liver models. However, clinical studies in transplantation demonstrated only modest transaminase improvements with no significant benefit on patient or graft survival.", "population_specificity": "Patients undergoing major liver surgery or transplantation, and experimental models of liver ischemia-reperfusion injury.", "effective_dosage": "Most widely used concentration was 150 mg/kg by intravenous bolus.", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:59.943115+00:00"}
{"study_id": 76418, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the potential of N-Acetylcysteine as an antioxidant to mitigate lung toxicity caused by sulfur mustard exposure.", "results_summary": "The study suggests N-Acetylcysteine may help counteract oxidative stress and inflammation in the lung following sulfur mustard poisoning, though specific efficacy data are not detailed. It is listed among other potential therapeutic interventions for lung injury.", "population_specificity": "Animal and cell culture models (not human subjects).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:00.010403+00:00"}
{"study_id": 76419, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 30, "study_goal": "The researchers aimed to evaluate the therapeutic potential of N-acetylcysteine (NAC) as an antioxidant adjunct in a lupus nephritis patient.", "results_summary": "The patient showed improved glutathione levels, normalized malondialdehyde levels, and better urinary protein levels, blood counts, and organ function after NAC administration. However, the study emphasizes the need for a well-controlled trial to confirm these findings.", "population_specificity": "A 46-year-old lupus nephritis patient.", "effective_dosage": "1800 mg orally (frequency not specified).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:01.132837+00:00"}
{"study_id": 76420, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine if N-Acetylcysteine (NAC) reduces oxidative stress and endothelial dysfunction caused by intravenous iron therapy in hemodialysis patients.", "results_summary": "NAC significantly reduced oxidative stress (measured by MDA) compared to placebo but did not show statistically significant effects on HsCRP. It also reduced endothelial dysfunction, though not significantly except for reflection index (RI).", "population_specificity": "14 adult hemodialysis patients", "effective_dosage": "600 mg twice daily", "study_duration": "10 days prior to intravenous iron therapy", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:06.098064+00:00"}
{"study_id": 76422, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to determine if N-Acetylcysteine (NAC) as a mucolytic and antioxidant agent improves symptoms of asthma exacerbation when added to standard treatment.", "results_summary": "The study found no significant difference in symptom scores (wheezing, cough, dyspnea, sputum, expectoration, night sleep) or morning PEFR between NAC and placebo groups, concluding NAC had no significant effect on asthma exacerbation treatment.", "population_specificity": "50 patients (17 male, 33 female, mean age 48.94\u00b113.68) with asthma exacerbation.", "effective_dosage": "600 mg twice daily (b.d.)", "study_duration": "5 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:07.233109+00:00"}
{"study_id": 76423, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC) provides nephroprotection against contrast-induced nephropathy (CIN) in patients undergoing peripheral arterial angiography.", "results_summary": "NAC showed a significant reduction in serum creatinine levels by the third postprocedure day but had equivocal effects on urinary retinol binding protein and albumin-creatinine ratio compared to hydration alone. One patient in the NAC group developed CIN versus three in the control group, though the difference was not statistically significant.", "population_specificity": "40 patients undergoing peripheral arterial angiography.", "effective_dosage": "Not specified (oral NAC in addition to intravenous hydration).", "study_duration": "Intervention lasted until the third postprocedure day.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:07.830810+00:00"}
{"study_id": 76425, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine reduces mortality, morbidity, or resource utilization in cardiac surgery patients.", "results_summary": "The study found no significant benefit of NAC in reducing acute renal failure, atrial fibrillation, mortality, or other postoperative complications compared to placebo. Current evidence does not support NAC's efficacy for clinically important outcomes in cardiac surgery.", "population_specificity": "1,407 patients undergoing cardiac surgery across 15 randomized studies.", "effective_dosage": "Not specified", "study_duration": "Perioperative (exact duration not specified)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:07.854535+00:00"}
{"study_id": 76424, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "To evaluate the efficacy of topical N-acetylcysteine (NAC) therapy in patients with meibomian gland dysfunction (MGD).", "results_summary": "Topical NAC therapy significantly improved fluorescein break-up time (FBUT) and Schirmer scores compared to baseline and controls. It also alleviated symptoms like ocular burning, foreign body sensation, and itching more effectively than artificial tears.", "population_specificity": "Twenty patients with MGD.", "effective_dosage": "5% NAC applied topically 4 times daily.", "study_duration": "1 month.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:08.070634+00:00"}
{"study_id": 76426, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to determine if N-Acetylcysteine could prevent or reduce cisplatin-induced ototoxicity compared to salicylate or no additional treatment.", "results_summary": "N-Acetylcysteine reduced cisplatin-induced ototoxic damage at high frequencies (10,000 and 12,000 Hz), but no difference was detected in auditory brainstem response outcomes between N-Acetylcysteine and salicylate.", "population_specificity": "54 patients (28 females, 26 males; mean age 37\u00b19.5 years) receiving cisplatin chemotherapy for solid organ tumors.", "effective_dosage": "600 mg/day", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:09.752399+00:00"}
{"study_id": 76421, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the efficacy of intravenous N-acetylcysteine combined with nutritional support in improving survival and biological parameters in patients with severe acute alcoholic hepatitis.", "results_summary": "The study found no significant survival benefit or early biological improvement with N-acetylcysteine compared to placebo, with similar 1-month and 6-month survival rates and no differences in infection rates or hepatorenal syndrome incidence.", "population_specificity": "Patients with biopsy-proven severe acute alcoholic hepatitis (mDF \u226532).", "effective_dosage": "High doses intravenously (specific amount not stated) for 14 days.", "study_duration": "14 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:10.742050+00:00"}
{"study_id": 76427, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to summarize recent data on the efficacy of preventive interventions, including N-Acetylcysteine, for contrast-induced acute kidney injury.", "results_summary": "The study found conflicting data on N-Acetylcysteine's efficacy due to methodological limitations in past studies, with no clear consensus on its effectiveness.", "population_specificity": "High-risk patients undergoing intravascular administration of iodinated contrast media.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:13.669206+00:00"}
{"study_id": 76428, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 80, "quality_score": 70, "study_goal": "To explore the efficacy of oral N-acetylcysteine (NAC) supplementation for anemia and oxidative stress in hemodialysis (HD) patients.", "results_summary": "NAC supplementation significantly increased hematocrit and reduced oxidative stress markers (8-isoprostane and oxidized LDL) in HD patients, with no severe adverse effects reported. NAC was also a significant predictor of positive outcomes in uremic anemia.", "population_specificity": "Hemodialysis (HD) patients in an outpatient unit.", "effective_dosage": "200 mg orally thrice a day.", "study_duration": "3 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:16.153819+00:00"}
{"study_id": 76431, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the potential of N-Acetylcysteine as a novel therapy for preventing postoperative atrial fibrillation (POAF) in cardiac surgery patients, particularly in those intolerant to beta-blockers or as add-on therapy.", "results_summary": "Preliminary evidence suggests N-Acetylcysteine may be effective in preventing POAF, but large-scale clinical studies are needed to confirm its benefits before routine use.", "population_specificity": "Patients undergoing cardiac surgery at risk for postoperative atrial fibrillation.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:16.289196+00:00"}
{"study_id": 76429, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the efficacy of N-Acetylcysteine (NAC) and magnesium in reducing oxidative stress and improving recovery in South Indian patients undergoing coronary artery bypass grafting (CABG).", "results_summary": "NAC administration before aortic cross-clamp release significantly reduced lipid peroxidation and improved antioxidant enzyme levels, erythrocyte ATPase, and cardiac markers, correlating with fewer postoperative abnormalities. NAC was effective but magnesium showed better recovery mediation.", "population_specificity": "South Indian patients undergoing CABG surgery.", "effective_dosage": "Not specified (administered just before aortic cross-clamp release).", "study_duration": "Single administration during surgery.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:16.839908+00:00"}
{"study_id": 76430, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to evaluate whether N-Acetylcysteine (NAC) added to renin-angiotensin system blockade could improve blood pressure and cardiovascular risk markers in non-diabetic CKD patients with albuminuria.", "results_summary": "The study found no significant changes in blood pressure, albuminuria, or homocysteine levels after eight weeks of NAC therapy, indicating no measurable effect on cardiovascular risk markers in this population.", "population_specificity": "Non-diabetic patients with albuminuria (30-915 mg per creatinine mg) and normal or slightly decreased kidney function (eGFR 61-163 ml/min).", "effective_dosage": "1200 mg/day", "study_duration": "8 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:17.113592+00:00"}
{"study_id": 76432, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to determine whether prophylactic administration of N-Acetylcysteine (NAC) prevents acute kidney injury (AKI) following cardiac surgery.", "results_summary": "The study found that prophylactic NAC administration did not reduce the incidence of AKI, postoperative complications, interventions, mortality, or ICU stay length in cardiac surgery patients. Meta-analyses and RCTs supported these findings across different risk groups.", "population_specificity": "Cardiac surgery patients, including low-risk, high-risk, and high-risk patients with pre-existing chronic kidney disease.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:18.345345+00:00"}
{"study_id": 76433, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to evaluate whether N-Acetylcysteine, when combined with therapeutic hypothermia, could enhance neuroprotection in infants with hypoxic ischaemic encephalopathy.", "results_summary": "The abstract suggests that N-Acetylcysteine is among the agents that may provide additive or synergistic neuroprotective effects when combined with therapeutic hypothermia, though specific outcomes for N-Acetylcysteine alone are not detailed.", "population_specificity": "Infants with hypoxic ischaemic encephalopathy.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:18.894119+00:00"}
{"study_id": 76417, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the role of N-acetylcysteine as part of a combination therapy for idiopathic pulmonary fibrosis (IPF) and other fibrosing lung diseases.", "results_summary": "The study weakly endorsed a combination therapy including N-acetylcysteine for IPF, suggesting it may be part of an effective treatment strategy, though enrollment in trials for newer therapies was recommended as best practice.", "population_specificity": "Patients with idiopathic pulmonary fibrosis (IPF) and other fibrosing lung diseases.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:21.573002+00:00"}
{"study_id": 76434, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC) affects serum creatinine levels independently of actual kidney function in patients with stage 3 chronic kidney disease.", "results_summary": "The study found no significant differences between NAC and placebo groups in changes to serum creatinine, cystatin C, urine protein, urine creatinine, or creatinine clearance at any measured time point. NAC had no short-term effect on creatinine levels and did not reduce urine protein excretion within 48 hours of treatment.", "population_specificity": "Patients with stage 3 chronic kidney disease (n = 60), mean age 70 years, 75% men, 50% with diabetes.", "effective_dosage": "1,200 mg oral NAC, 4 doses administered at 12-hour intervals.", "study_duration": "48 hours (4 doses over 2 days).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:23.674101+00:00"}
{"study_id": 76436, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine pretreatment could destroy H. pylori biofilm and improve antibiotic eradication rates in patients with prior treatment failures.", "results_summary": "N-Acetylcysteine pretreatment significantly improved H. pylori eradication rates (65% vs. 20%) compared to no pretreatment, and biofilms persisted only in unsuccessfully treated participants. Genotypes did not influence outcomes.", "population_specificity": "40 subjects with a history of at least 4 H. pylori eradication failures.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:24.763779+00:00"}
{"study_id": 76435, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 60, "quality_score": 85, "study_goal": "The researchers aimed to examine the pharmacokinetics and pharmacodynamics of oral N-acetylcysteine (NAC) in ESRD patients to assess its potential for reducing oxidative stress.", "results_summary": "NAC showed dose-related increases in plasma concentrations in ESRD patients, with reduced clearance leading to higher systemic exposure. It significantly lowered homocysteine levels but had no effect on other oxidative stress markers.", "population_specificity": "ESRD patients (24 participants) and healthy controls (7 participants).", "effective_dosage": "600 mg or 1200 mg every 12 hours.", "study_duration": "14 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:24.963475+00:00"}
{"study_id": 76439, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effectiveness of N-Acetylcysteine (N-AC) in preventing contrast-induced nephropathy (CIN) in high-risk patients.", "results_summary": "The study concluded that combining hydration (normal saline or NaHCO3) with N-AC is the cornerstone of CIN prevention, suggesting N-AC is effective in reducing CIN incidence.", "population_specificity": "High-risk patients undergoing contrast media administration.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:26.078469+00:00"}
{"study_id": 76437, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to determine if N-acetylcysteine could neutralize the oxidative and inflammatory effects of iron administration during haemodialysis.", "results_summary": "N-acetylcysteine significantly reduced malondialdehyde levels (a marker of oxidative stress) when administered with a low iron dose (50 mg), but had no effect on other inflammatory or endothelial dysfunction markers. Haemodialysis itself increased oxidative stress and inflammation, while iron had minor effects on inflammation and oxidative stress.", "population_specificity": "40 patients undergoing haemodialysis.", "effective_dosage": "Not specified (infused before iron sucrose at 50 or 100 mg).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:26.192689+00:00"}
{"study_id": 76438, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 40, "quality_score": 85, "study_goal": "The researchers aimed to assess whether high-dose N-acetylcysteine reduces contrast-induced nephropathy and reperfusion injury in ST-segment elevation myocardial infarction patients undergoing primary angioplasty with moderate contrast volumes.", "results_summary": "N-acetylcysteine reduced oxidative stress markers by 20% but did not significantly reduce contrast-induced nephropathy or improve myocardial salvage index compared to placebo. The study found no additional clinical benefit over placebo for these outcomes.", "population_specificity": "ST-segment elevation myocardial infarction patients undergoing primary angioplasty with moderate contrast volumes.", "effective_dosage": "2 x 1,200 mg/day for 48 hours.", "study_duration": "48 hours.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:26.262926+00:00"}
{"study_id": 76440, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 90, "quality_score": 75, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC) could protect against hepatotoxicity induced by first-line anti-tuberculosis drugs.", "results_summary": "NAC significantly reduced liver enzyme levels and prevented hepatotoxicity in patients receiving anti-TB drugs, with no cases of hepatotoxicity in the NAC group compared to 37.5% in the control group.", "population_specificity": "New tuberculosis patients aged 60 years or older.", "effective_dosage": "Not specified in the abstract.", "study_duration": "2 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:28.824502+00:00"}
{"study_id": 76441, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 50, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC) could help lower homocysteine (Hcy) levels in Alzheimer's disease (AD) pathology.", "results_summary": "The abstract suggests that NAC, along with B-vitamin supplements, may help lower Hcy levels, which are implicated in neuroinflammatory oxidative stress and AD pathological cascades. However, specific efficacy data or outcomes are not detailed.", "population_specificity": "Individuals with Alzheimer's disease or related neuroinflammatory oxidative stress.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:30.736780+00:00"}
{"study_id": 76442, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore whether N-Acetylcysteine (NAC) could mitigate illness progression in recurrent affective disorders by addressing sensitization to stressors, episodes, and cocaine abuse.", "results_summary": "NAC was found to decrease the severity of bipolar affective illness and reduce cocaine reinstatement and craving, suggesting potential benefits in addressing multiple factors driving illness progression. The study highlights NAC's role in modulating BDNF levels, which may underlie its therapeutic effects.", "population_specificity": "Individuals with recurrent affective disorders and comorbid cocaine abuse.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:31.685519+00:00"}
{"study_id": 76444, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 65, "study_goal": "The researchers aimed to evaluate whether N-Acetylcysteine reduces the risk of acute kidney injury (AKI) in adults undergoing cardiac surgery.", "results_summary": "The study found that N-Acetylcysteine did not reduce the risk for AKI in cardiac surgery patients. The analysis was part of a broader review of multiple interventions, with most studies being small and of varying quality.", "population_specificity": "Adults undergoing cardiac surgery.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:32.245641+00:00"}
{"study_id": 76443, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine if N-Acetylcysteine (NAC) combined with ciprofloxacin could improve biochemical and inflammatory markers in patients with partial bile duct obstruction before undergoing ERCP.", "results_summary": "NAC significantly reduced ALP, GGT, WBC, CRP, and NE% levels compared to placebo, suggesting it may be a beneficial therapeutic option for partial cholestatic patients awaiting ERCP.", "population_specificity": "102 patients with choledocholithiasis and choledochal dilatations.", "effective_dosage": "1800 mg/d intravenously.", "study_duration": "7 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:33.405109+00:00"}
{"study_id": 76446, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to evaluate N-Acetylcysteine as a potential therapeutic agent to augment neuroprotection when combined with hypothermia in neonates with hypoxic-ischemic encephalopathy.", "results_summary": "The abstract suggests N-Acetylcysteine is discussed as a future potential therapeutic agent that might enhance the neuroprotective effects of hypothermia, but specific results or outcomes are not detailed.", "population_specificity": "Neonates with hypoxic-ischemic encephalopathy.", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:33.833932+00:00"}
{"study_id": 76445, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to determine if N-Acetylcysteine (NAC) modifies pro-antioxidant status, affects hematological responses, influences erythropoietin (EPO) secretion, and enhances exercise performance in healthy men.", "results_summary": "NAC significantly improved antioxidant status (increased glutathione, reduced oxidative damage markers) and affected hematological indices (increased EPO, hemoglobin, hematocrit) but did not enhance exercise performance.", "population_specificity": "Fifteen healthy men.", "effective_dosage": "1,200 mg daily for 8 days prior, then 600 mg on the day of exercise trial.", "study_duration": "8 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:34.737107+00:00"}
{"study_id": 76447, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether prophylactic N-Acetylcysteine (NAC) administration is effective in preventing contrast-induced nephropathy (CIN) in patients undergoing coronary angiography (CAG) and/or percutaneous coronary intervention (PCI).", "results_summary": "NAC significantly reduced serum creatinine and increased creatinine clearance, suggesting it effectively prevents CIN. Blood beta-2 microglobulin levels also significantly decreased in the NAC group, indicating renal protection.", "population_specificity": "Patients undergoing CAG and/or PCI, particularly those with chronic kidney disease (CKD).", "effective_dosage": "704 mg orally twice daily.", "study_duration": "Administered until 48 hours after CAG and/or PCI.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:36.297583+00:00"}
{"study_id": 76448, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to evaluate the role of N-Acetylcysteine in managing smoke inhalation injury, particularly its potential to mitigate inflammatory cascades and airway obstruction.", "results_summary": "The study suggests that nebulized N-Acetylcysteine, alongside other treatments like \u03b22-agonists and heparin, has a role in managing smoke inhalation injury by addressing airway obstruction and inflammation, though specific efficacy data are not detailed.", "population_specificity": "Burn victims with smoke inhalation injury.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:36.637857+00:00"}
{"study_id": 76449, "supplement_id": 1364, "safety_score": "90", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to determine the effect of oral N-Acetylcysteine (NAC) on plasma levels of inflammatory and oxidative stress markers in peritoneal dialysis (PD) patients.", "results_summary": "NAC treatment significantly reduced IL-6 levels but did not significantly affect other inflammatory or oxidative stress markers. The intervention caused no side effects.", "population_specificity": "30 peritoneal dialysis patients (40% males, age 52 \u00b1 13 years), with 22 completing the study.", "effective_dosage": "2 x 600 mg daily", "study_duration": "8 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:38.656550+00:00"}
{"study_id": 76450, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 80, "quality_score": 75, "study_goal": "To review recent findings on idiosyncratic drug-induced liver injury (DILI), including the potential benefits of N-acetylcysteine for acute liver failure caused by medications or herbal agents.", "results_summary": "N-acetylcysteine appears beneficial for patients with acute liver failure caused by medications or herbal agents, though the abstract does not provide detailed efficacy data. The study highlights its potential role in managing DILI-related liver failure.", "population_specificity": "Patients with acute liver failure caused by medications or herbal agents.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:39.543686+00:00"}
{"study_id": 76451, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to evaluate whether N-Acetylcysteine (NAC) improves liver graft performance and reduces post-operative acute kidney injury (AKI) in liver transplant patients.", "results_summary": "IV NAC did not improve survival, graft function, or AKI risk, though some patients showed increased GSH levels, which correlated with fewer AKI cases. Additional risk factors for AKI included female gender, high baseline bilirubin, and elevated serum creatinine.", "population_specificity": "100 patients undergoing orthotopic liver transplant (50 placebo, 50 NAC).", "effective_dosage": "Loading dose of 140 mg/kg IV over 1 hour, followed by 70 mg/kg IV every 4 hours for 12 doses.", "study_duration": "Intervention administered over approximately 48 hours (12 doses every 4 hours).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:42.639219+00:00"}
{"study_id": 76453, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare serum creatinine and cystatin C levels in patients with chronic kidney disease undergoing coronary angiography to evaluate the effectiveness of N-Acetylcysteine (NAC) in preventing radiocontrast-induced nephropathy (RCIN).", "results_summary": "The study found no significant difference in serum creatinine or cystatin C levels before and after angiography in patients treated with NAC, suggesting that both markers are equivalent for evaluating NAC's preventive effect. The prophylactic treatment regime was deemed effective in protecting high-risk patients against RCIN.", "population_specificity": "Patients with chronic kidney disease undergoing coronary angiography.", "effective_dosage": "A total of three doses of NAC given orally (specific dosage not detailed).", "study_duration": "24 hours after angiography.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:43.110390+00:00"}
{"study_id": 76452, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to compare the efficacy of saline infusion alone, saline plus N-Acetylcysteine (NAC), and sodium bicarbonate infusion in preventing contrast-induced nephropathy (CIN) in patients undergoing coronary procedures.", "results_summary": "The study found no significant difference in CIN incidence between the three treatment groups, suggesting that NAC did not provide additional benefit over saline infusion alone in preventing CIN.", "population_specificity": "156 patients with baseline creatinine levels \u2265 1.2 mg/dL undergoing coronary angiography and/or percutaneous coronary intervention.", "effective_dosage": "Not specified", "study_duration": "Within 5 days from contrast exposure", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:44.341970+00:00"}
{"study_id": 76454, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 80, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine, in combination with atorvastatin and standard hydration, reduces the risk of contrast-induced nephropathy in CKD patients undergoing coronary procedures.", "results_summary": "The study found no significant difference in CIN occurrence between the atorvastatin and placebo groups, both of which received N-Acetylcysteine. N-Acetylcysteine's standalone efficacy was not isolated, but the combined regimen did not reduce CIN risk.", "population_specificity": "Patients with chronic kidney disease (estimated creatinine clearance <60 ml/min) undergoing coronary angiography or angioplasty.", "effective_dosage": "1,200 mg orally twice daily.", "study_duration": "48 hours before and 48 hours after contrast medium administration.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:44.493755+00:00"}
{"study_id": 76455, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the total hospitalization charges and length of stay between patients treated with enteral versus IV acetylcysteine for acetaminophen overdose.", "results_summary": "IV acetylcysteine was associated with significantly lower hospitalization costs ($7,607.82 vs. $18,287.63) and shorter hospital stays (4 days vs. 7 days) compared to enteral acetylcysteine. Both forms were effective, but IV therapy was more cost-effective.", "population_specificity": "Adults over 18 years admitted for acute acetaminophen overdose within 24 hours, with no transplant history.", "effective_dosage": "Not specified", "study_duration": "Treatment duration varied (enteral: 7 days, IV: 4 days on average).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:45.463363+00:00"}
{"study_id": 76457, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to determine the cost-effectiveness of a treatment strategy using TPMT testing before initiating azathioprine, NAC, and steroids in idiopathic pulmonary fibrosis (IPF).", "results_summary": "The study found that combining azathioprine, NAC, and steroids reduced IPF disease progression by 14% over 12 months. TPMT testing before treatment was cost-effective, particularly when the prevalence of abnormal TPMT alleles was higher.", "population_specificity": "Patients with idiopathic pulmonary fibrosis (IPF).", "effective_dosage": "Not specified", "study_duration": "12 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:46.648547+00:00"}
{"study_id": 76458, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to determine whether N-acetylcysteine could rescue neprilysin (NEP) from oxidative modification caused by HNE or Abeta, potentially preserving its activity.", "results_summary": "N-acetylcysteine (10-100 microM) reduced HNE adduction on NEP after HNE or Abeta treatment, suggesting it may protect NEP from oxidative damage and maintain its catalytic activity.", "population_specificity": "SH-SY5Y cells (a human neuroblastoma cell line)", "effective_dosage": "10 to 100 microM", "study_duration": "24 hours", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:48.171496+00:00"}
{"study_id": 76460, "supplement_id": 1364, "safety_score": "90", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate whether perioperative N-acetylcysteine could prevent renal dysfunction in infants undergoing cardiac surgery for dextro-transposition of the great arteries.", "results_summary": "N-acetylcysteine improved urine output, shortened time to negative fluid balance, attenuated the rise in creatinine, and reduced ICU stay compared to placebo, with no serious adverse events reported.", "population_specificity": "Neonates undergoing the arterial switch operation for dextro-transposition of the great arteries.", "effective_dosage": "Not specified", "study_duration": "Perioperative (exact duration not specified)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:50.814468+00:00"}
{"study_id": 76459, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 50, "study_goal": "The researchers aimed to evaluate the potential of N-Acetylcysteine as a neuroprotective agent against oxaliplatin-induced neurotoxicity.", "results_summary": "The abstract mentions N-Acetylcysteine as one of several neuroprotective agents considered, but none, including N-Acetylcysteine, were proven effective in large, controlled clinical trials.", "population_specificity": "Patients treated with oxaliplatin, particularly those with colorectal cancer and other cancers (ovary, lung, breast, liver) or non-Hodgkin's lymphoma.", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:51.742468+00:00"}
{"study_id": 76463, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine whether N-acetylcysteine could suppress oxidative stress-induced Tissue Factor (TF) expression in human coronary artery endothelial cells.", "results_summary": "The study found that pre-treatment with N-acetylcysteine, along with other antioxidants, suppressed oxidative stress-induced TF expression, suggesting a potential role in mitigating atherothrombotic processes.", "population_specificity": "Human coronary artery endothelial cells (in vitro study).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:52.549256+00:00"}
{"study_id": 76462, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to review the potential mechanism by which oxidative stress mediates fibrogenesis induced by TGF-beta and assess the therapeutic value of N-Acetylcysteine in fibrotic diseases.", "results_summary": "The abstract suggests that N-Acetylcysteine, as a precursor of GSH, has been used clinically for treating fibrotic diseases, though the biological significance of GSH depletion in fibrosis remains unclear. The study highlights the role of oxidative stress in TGF-beta-induced fibrogenesis but does not provide specific efficacy data for N-Acetylcysteine.", "population_specificity": "Human fibrotic diseases and experimental fibrosis models (not specified further).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:53.196209+00:00"}
{"study_id": 76461, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effects of high-dose N-Acetylcysteine on preventing contrast-induced acute kidney injury (CI-AKI) in patients with acute myocardial infarction undergoing percutaneous coronary intervention.", "results_summary": "The study used high-dose N-Acetylcysteine alongside hydration to assess its impact on CI-AKI incidence and tissue-level perfusion, but specific efficacy results for N-Acetylcysteine alone were not detailed in the abstract.", "population_specificity": "Patients admitted for ST-segment elevation acute myocardial infarction undergoing primary percutaneous coronary intervention.", "effective_dosage": "1200 mg intravenously during the procedure and 1200 mg orally two times daily for the next 48 hours.", "study_duration": "48 hours post-procedure.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:53.554545+00:00"}
{"study_id": 76456, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to clarify the benefits of N-acetylcysteine in preventing contrast-induced nephropathy in high-risk renal patients undergoing coronary angiography.", "results_summary": "N-acetylcysteine significantly reduced the incidence of contrast-induced nephropathy (5.1% vs. 23.8% in placebo) and was an independent protective factor against adverse outcomes, though no significant difference in mortality rates was observed.", "population_specificity": "Patients with chronic renal failure (plasma creatinine \u22651.4 mg/dL) undergoing coronary angiography.", "effective_dosage": "600 mg every 12 hours intravenously.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:54.068591+00:00"}
{"study_id": 76464, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 65, "study_goal": "The researchers aimed to explore the potential of N-Acetylcysteine as an antioxidant intervention for preventing postoperative atrial fibrillation (POAF) following cardiac surgery.", "results_summary": "The abstract suggests N-Acetylcysteine is among the emerging antioxidant strategies that may help prevent POAF by targeting oxidative stress and NADPH oxidase activation, though specific efficacy data are not detailed.", "population_specificity": "Patients undergoing cardiac surgery at risk for postoperative atrial fibrillation.", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:54.133885+00:00"}
{"study_id": 76465, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine prevents contrast-induced nephropathy (CIN) based on cystatin C levels in patients undergoing coronary angiography.", "results_summary": "N-Acetylcysteine significantly reduced the incidence of cystatin C-based CIN (5.0% vs. 15.1% in controls) and showed a trend toward reducing creatinine-based CIN. Cystatin C was found to be a more sensitive marker for early CIN than creatinine.", "population_specificity": "166 patients with apparently normal renal function undergoing elective coronary angiography.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:56.718827+00:00"}
{"study_id": 201146, "supplement_id": 1364, "safety_score": "90", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the benefits of NAC supplementation on physical performance and laboratory biomarkers in adult men.", "results_summary": "NAC supplementation improved exercise performance, antioxidant capacity, and glutathione homeostasis, but showed no clear benefits for haematological markers, inflammatory response, or muscle behaviour. No serious adverse events were reported.", "population_specificity": "Adult men", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:58.588753+00:00"}
{"study_id": 201145, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine how NAC supplementation affects biomarkers related to oxidative stress, inflammation, muscle damage, and recovery after physical exertion.", "results_summary": "NAC supplementation significantly reduced muscle soreness, lactate, IL-6, and TBARS levels while increasing GSH concentration, but had no significant effect on TNF-\u03b1, CK, or GSSG levels.", "population_specificity": "Individuals undergoing physical exertion (exercise or sports-related activity).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:58.787980+00:00"}
{"study_id": 201147, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 40, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy of acute and chronic NAC administration on recovery biomarkers by analyzing existing trials.", "results_summary": "The meta-analysis found no significant effects of acute NAC administration on lactate, pH, or VO2. The study noted conflicting results across existing trials regarding NAC's impact on recovery.", "population_specificity": "1,388 participants across 37 studies (specific population not detailed in the abstract).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:00.259885+00:00"}
{"study_id": 201148, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the potential of N-acetylcysteine as an antioxidant to ameliorate oxidative stress in peritoneal dialysis patients.", "results_summary": "The study suggests N-acetylcysteine is a promising antioxidant for reducing oxidative stress in peritoneal dialysis, which is linked to inflammation, cardiovascular disease, and mortality. However, the abstract does not provide specific efficacy data or outcomes from N-acetylcysteine supplementation.", "population_specificity": "Chronic kidney disease patients undergoing peritoneal dialysis.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:01.454041+00:00"}
{"study_id": 201151, "supplement_id": 1364, "safety_score": "50", "efficacy_score": 40, "quality_score": 70, "study_goal": "To review the effects of NAC supplementation on sport performance and evaluate the risk of adverse effects.", "results_summary": "Initial research suggested positive performance effects with NAC, but the study concludes it cannot be recommended further due to unclear risk of side effects and inconsistent results. Suboptimal reporting in the literature complicates meta-analysis and conclusions.", "population_specificity": "Elite athletes (implied by focus on sport performance).", "effective_dosage": "Typical daily dose of 5.8 g\u00b7d (exact frequency not specified).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:01.765502+00:00"}
{"study_id": 201152, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to determine if N-Acetylcysteine (NAC) supplementation affects exercising arm blood flow and muscle oxygenation characteristics during severe-intensity exercise.", "results_summary": "NAC supplementation increased plasma cysteine levels but did not significantly alter time to exhaustion, limb blood flow, or muscle oxygenation during exercise compared to placebo.", "population_specificity": "Eight healthy nonendurance-trained men (21.8 \u00b1 1.2 years).", "effective_dosage": "70 mg/kg, single oral dose 60 minutes prior to exercise.", "study_duration": "Acute (single-dose intervention).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:02.602497+00:00"}
{"study_id": 201150, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to determine whether oxidative stress mediates alterations in lymphocyte subsets following inspiratory resistive breathing (IRB) and whole-body exercise (WBE), and whether N-Acetylcysteine (as an antioxidant) could mitigate these changes.", "results_summary": "Antioxidant supplementation (N-Acetylcysteine) abolished IRB-induced lymphocyte subset alterations, including changes in natural killer cells, T helper cells, and CD4/CD8 ratio, and blunted cytotoxic T-cell percentage increases. It also affected CD8+ CD45RA+ cell percentages in both WBE and IRB.", "population_specificity": "Six healthy nonathletes", "effective_dosage": "Not specified", "study_duration": "45 minutes per session (two sessions each for WBE and IRB)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:03.175107+00:00"}
{"study_id": 201153, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine if N-acetylcysteine supplementation could attenuate increased airway responsiveness caused by diesel exhaust exposure, particularly in individuals with baseline airway hyper-responsiveness.", "results_summary": "N-acetylcysteine reduced baseline airway responsiveness by 20% in hyper-responsive individuals and abrogated the 42% increase in airway responsiveness following diesel exhaust exposure, showing protective effects against diesel exhaust-induced airway changes.", "population_specificity": "26 non-smokers, including individuals with baseline airway hyper-responsiveness.", "effective_dosage": "600 mg three times daily.", "study_duration": "6 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:04.674660+00:00"}
{"study_id": 201154, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine whether short-term oral N-acetylcysteine (NAC) supplementation improves athletic performance by enhancing redox balance and reducing inflammation during intense training.", "results_summary": "NAC improved sprint performance, increased postexercise antioxidant capacity, reduced oxidative damage, attenuated inflammation, and enhanced nuclear factor \u03baB activity in well-trained triathletes.", "population_specificity": "10 well-trained triathletes (8 completed both trials)", "effective_dosage": "1200 mg per day", "study_duration": "9 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:06.706981+00:00"}
{"study_id": 201155, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not specifically address N-Acetylcysteine; it focuses on idiosyncratic drug-induced liver injury (DILI) and its causes, risk factors, and diagnostic approaches.", "results_summary": "The study does not report findings on N-Acetylcysteine; it discusses general DILI epidemiology, risk factors, and diagnostic methods.", "population_specificity": "Not specified for N-Acetylcysteine", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:07.598538+00:00"}
{"study_id": 201157, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to examine how N-Acetylcysteine (NAC) supplementation affects skeletal muscle performance and redox-sensitive signaling during the inflammatory and repair phases following exercise-induced microtrauma.", "results_summary": "NAC attenuated inflammatory markers and muscle damage, blunted redox-sensitive signaling pathways, and reduced strength loss initially but disrupted muscle repair and performance recovery compared to placebo.", "population_specificity": "10 men", "effective_dosage": "20 mg/kg/day", "study_duration": "8 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:09.133317+00:00"}
{"study_id": 201158, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to assess whether N-Acetylcysteine (NAC) supplementation could effectively prevent postoperative atrial fibrillation (POAF) in patients undergoing cardiac surgery.", "results_summary": "NAC supplementation significantly reduced the incidence of POAF compared to controls but had no effect on hospital length of stay. The study concluded that NAC may be effective for POAF prevention, though the quality of existing studies was noted as poor.", "population_specificity": "Adult patients undergoing cardiac surgery.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:10.080231+00:00"}
{"study_id": 201156, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers aimed to determine the effects of N-Acetylcysteine (NAC) on metabolism and performance during high-intensity interval exercise (HIIE) and a 10-minute time-trial (TT10) in trained cyclists.", "results_summary": "NAC decreased lipid peroxidation, increased fat oxidation and blood glucose during HIIE, and reduced blood lactate post-TT10, but it also lowered median EMG frequency and decreased mean power output during TT10, suggesting impaired performance.", "population_specificity": "Nine well-trained male cyclists with high VO2peak and peak power output.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Two trials performed 7 days apart.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:11.249866+00:00"}
{"study_id": 201159, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the effects of short-term N-acetylcysteine (NAC) supplementation on muscle fatigue, VO(2max), and oxidative stress markers in sedentary men.", "results_summary": "NAC supplementation improved muscle fatigue and VO(2max), maintained total antioxidant capacity (TAC), and controlled lactate production, but had no significant influence on creatine kinase (CK) and tumor necrotic factor-alpha (TNF-\u03b1) levels.", "population_specificity": "Twenty-nine sedentary men (13 controls, 16 in the supplement group).", "effective_dosage": "1,200 mg daily", "study_duration": "7 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:11.250511+00:00"}
{"study_id": 29282, "supplement_id": 1366, "safety_score": "85", "efficacy_score": 90, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety, tolerability, and antidepressant effects of inhaled N,N-Dimethyltryptamine (DMT) in patients with treatment-resistant depression (TRD).", "results_summary": "The study found that vaporized DMT was safe, well-tolerated, and produced rapid and sustained antidepressant effects, with significant reductions in depression scores and suicidal ideation. Response and remission rates were high (85.71% and 57.14%, respectively), lasting up to 3 months.", "population_specificity": "Fourteen patients with treatment-resistant depression (6 female).", "effective_dosage": "15 mg and 60 mg (dose-escalation study).", "study_duration": "Effects were assessed up to 3 months post-administration.", "interactions": "None mentioned (subpopulation on antidepressants showed similar safety outcomes).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:12.909422+00:00"}
{"study_id": 29284, "supplement_id": 1366, "safety_score": "85", "efficacy_score": null, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the short-term safety and tolerability of 5-MeO-DMT in human subjects through a systematic review of clinical trials.", "results_summary": "The study found that 5-MeO-DMT has a favorable short-term safety and tolerability profile, with no serious adverse events or dropouts reported across three clinical trials. However, the data is limited, and further research is needed to assess chronic adverse events.", "population_specificity": "Healthy volunteers and patients with treatment-resistant depression (total n=78).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:12.965530+00:00"}
{"study_id": 29286, "supplement_id": 1366, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to characterize the neurochemical, neurophysiological, and behavioral effects of DMT in rats to understand its mechanistic action and potential physiological role.", "results_summary": "DMT caused dose-dependent increases in serotonin and dopamine levels, altered EEG spectral power (reduced theta/low gamma, increased delta/medium/high gamma), and modulated functional connectivity. Endogenous DMT was detected at levels comparable to serotonin and dopamine, suggesting a physiological role.", "population_specificity": "Male and female adult rats", "effective_dosage": "0.75 mg/kg, 3.75 mg/kg, 7.5 mg/kg (intravenous)", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:16.531190+00:00"}
{"study_id": 29285, "supplement_id": 1366, "safety_score": "75", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to develop and evaluate a transdermal DMT patch for safe, non-hallucinogenic delivery, assessing its pharmacokinetics and behavioral effects.", "results_summary": "The transdermal DMT patch (F5) provided consistent, extended drug release at sub-hallucinogenic doses, achieving 77% bioavailability compared to IV administration, with no hallucinogenic effects observed at low plasma concentrations.", "population_specificity": "Male and female Swiss Webster mice", "effective_dosage": "Sub-hallucinogenic plasma concentrations not exceeding 60 ng/mL", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:16.559159+00:00"}
{"study_id": 29287, "supplement_id": 1366, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether chronic DMT administration could alleviate cognitive impairment and reduce A\u03b2 accumulation in a transgenic mouse model of Alzheimer's disease by modulating ER-mitochondria signaling via Sig-1r activation.", "results_summary": "Chronic DMT administration significantly improved cognitive function, reduced A\u03b2 accumulation, restored Sig-1r levels, and normalized ER-mitochondria interactions and calcium dynamics in 3\u00d7TG-AD mice. It also enhanced mitochondrial function by modulating oxidative phosphorylation and ATP synthase activity.", "population_specificity": "3\u00d7TG-AD transgenic mice (a model for Alzheimer's disease).", "effective_dosage": "2 mg/kg (chronic administration).", "study_duration": "3 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:18.159702+00:00"}
{"study_id": 29288, "supplement_id": 1366, "safety_score": "85", "efficacy_score": 90, "quality_score": 88, "study_goal": "To investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BPL-003, an intranasal formulation of 5-MeO-DMT, in healthy participants.", "results_summary": "BPL-003 was well tolerated with mild adverse events, showed rapid absorption and elimination, and induced dose-proportional increases in mystical experiences and consciousness-altering effects.", "population_specificity": "Healthy, psychedelic-na\u00efve participants (n=44).", "effective_dosage": "1-12 mg BPL-003 (single ascending doses).", "study_duration": "Single-dose administration.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:18.842187+00:00"}
{"study_id": 29289, "supplement_id": 1366, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the potential therapeutic mechanisms of 5-MeO-DMT for treating alcohol use disorder (AUD) by reviewing existing literature.", "results_summary": "The study suggests that 5-MeO-DMT may alleviate AUD symptoms by inducing mystical experiences, ego-dissolution, and increasing psychological flexibility and mindfulness. Preliminary evidence also indicates modulation of neural oscillations and neuroplasticity, which could improve emotion regulation and inhibition.", "population_specificity": "Not specified (literature review, not a clinical trial).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:19.785483+00:00"}
{"study_id": 29293, "supplement_id": 1366, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to develop deuterated analogues of DMT to prolong its half-life and reduce clearance while maintaining similar pharmacological effects.", "results_summary": "The deuterated analogue D2-DMT showed the longest half-life and lowest clearance rate compared to DMT, with a similar receptor binding profile, making it a promising candidate for further evaluation.", "population_specificity": "In vitro (hepatocyte mitochondrial fractions) and receptor binding studies.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:20.850468+00:00"}
{"study_id": 29294, "supplement_id": 1366, "safety_score": "85", "efficacy_score": 90, "quality_score": 80, "study_goal": "The researchers aimed to investigate the safety and potential antidepressant effects of vaporized 5-MeO-DMT (GH001) in adults with treatment-resistant depression (TRD).", "results_summary": "GH001 was well tolerated and showed potent, ultra-rapid antidepressant effects, with 87.5% of patients in remission after individualized dosing. Remissions were observed as early as 2 hours post-administration, with significant reductions in MADRS scores.", "population_specificity": "Adults with treatment-resistant depression (TRD).", "effective_dosage": "6 mg, 12 mg, and 18 mg (individualized dosing regimen with up to three doses in a single day).", "study_duration": "Single-day administration with follow-up to day 7.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:22.345404+00:00"}
{"study_id": 29292, "supplement_id": 1366, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate the cytochrome P450 (CYP)-mediated metabolism of DMT, particularly focusing on CYP2D6, to better understand its metabolic pathways and potential safety implications.", "results_summary": "DMT was rapidly metabolized by CYP2D6, forming mono-, di-, and tri-oxygenated metabolites, likely through hydroxylation on the indole core. The study suggests that slow CYP2D6 metabolizers or those using CYP2D6 inhibitors may experience altered DMT metabolism, potentially impacting safety with ayahuasca intake.", "population_specificity": "In vitro study using recombinant human CYP enzymes and human liver microsomes (HLM).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "CYP2D6 inhibitors (e.g., harmine, SKF-525A) reduced DMT metabolism in HLM, while quinidine had no effect.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:22.654119+00:00"}
{"study_id": 29298, "supplement_id": 1366, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine whether DMT could prevent cerebral ischemic injury and its potential neuroprotective effects via sigma-1 receptor activation.", "results_summary": "DMT mitigated spreading depolarizations, reduced apoptotic and ferroptotic cells, and supported astrocyte survival, with effects comparable to the selective Sig-1R agonist PRE-084. These neuroprotective effects were counteracted by the Sig-1R antagonist NE-100.", "population_specificity": "Anesthetized rats subjected to global forebrain ischemia.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "Asenapine (serotonin receptor antagonist) was co-administered with DMT, showing attenuated effects compared to asenapine alone.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:25.725665+00:00"}
{"study_id": 29295, "supplement_id": 1366, "safety_score": "85", "efficacy_score": 70, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the preclinical and clinical pharmacokinetics, metabolism, and safety of N,N-Dimethyltryptamine (DMT) in healthy subjects to support its development for treating major depressive disorder.", "results_summary": "DMT showed rapid clearance (mean elimination half-life of 9-12 min) and was safe and well-tolerated across doses (9-21.5 mg). In vitro studies indicated reduced clearance via MAO-A and CYP2D6 inhibition, with low lipophilicity and plasma protein binding suggesting high availability for distribution and metabolism.", "population_specificity": "Healthy adults", "effective_dosage": "9-21.5 mg (DMT freebase) as a single 10-minute IV infusion", "study_duration": "Single-dose administration", "interactions": "Inhibition of MAO-A, CYP2D6, and to a lesser extent CYP2C19 reduced DMT clearance in vitro.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:26.795670+00:00"}
{"study_id": 29299, "supplement_id": 1366, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to develop and validate a green, time-saving method (HF-LPME) for detecting DMT and harmala alkaloids in human urine using LC-MS/MS.", "results_summary": "The study successfully developed an optimized HF-LPME method with high sensitivity (LoD 1.0 ng/ml for DMT) and accuracy, validated for linearity, precision, and recovery in human urine samples. The method was applied to authentic samples, proving feasibility.", "population_specificity": "Four human subjects (specific demographics not provided).", "effective_dosage": "Not specified (analysis focused on detection, not administration).", "study_duration": "Not specified (single-time urine sample analysis).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:27.153611+00:00"}
{"study_id": 29302, "supplement_id": 1366, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to develop a fast 2D-LC-(HRMS/MS) method for quantitative determination of DMT levels in plasma and brain tissue in an experimental model of cerebral ischemia/reperfusion.", "results_summary": "The study successfully developed a sensitive and reliable method to detect DMT in plasma and brain tissue, showing higher plasma DMT concentrations before hypoxia (49.3-114.3 ng/mL) compared to after hypoxia (10.6-96.1 ng/mL), and elevated brain DMT levels (2-6.1 ng/g) post-treatment.", "population_specificity": "Experimental rat model of cerebral ischemia/reperfusion.", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:28.468173+00:00"}
{"study_id": 29303, "supplement_id": 1366, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to demonstrate the in vivo neuroprotective effect of DMT following ischemia-reperfusion injury in the rat brain, focusing on its potential anti-apoptotic, pro-neurotrophic, and anti-inflammatory properties.", "results_summary": "DMT-treated rats showed significantly lower ischemic lesion volume and better functional recovery compared to controls, with evidence of reduced apoptosis, increased neurotrophic factors, and anti-inflammatory effects, all mediated through Sigma 1 receptor activation.", "population_specificity": "Male Wistar rats subjected to transient middle cerebral artery occlusion (MCAO).", "effective_dosage": "1 mg/kg bolus (IP) followed by 2 mg/kg/h maintenance dose over 24 hours.", "study_duration": "24 hours (acute intervention) with functional recovery monitored for 30 days.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:29.841675+00:00"}
{"study_id": 29306, "supplement_id": 1366, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to investigate the effects of N,N-Dimethyltryptamine (DMT) on anxiety and depression-related behaviors in rodents.", "results_summary": "DMT initially increased anxiety-like responses but later reduced anxiety by facilitating fear memory extinction and decreased immobility in the forced swim test, indicating antidepressant and anxiolytic effects.", "population_specificity": "Adult male Sprague-Dawley rats", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:30.158402+00:00"}
{"study_id": 29304, "supplement_id": 1366, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to investigate the effects of N,N-Dimethyltryptamine (DMT) on metabolic, microcirculatory, and histologic changes in a rat model of renal ischemia-reperfusion (I/R) injury.", "results_summary": "DMT administration before ischemia improved microcirculatory recovery and reduced histologic damage compared to untreated I/R injury, though tubular necrosis still occurred. The I/R+DMT group showed better compensation in blood flow and less severe histologic injuries than the untreated I/R group.", "population_specificity": "Anesthetized rats subjected to renal ischemia-reperfusion injury.", "effective_dosage": "Not specified in the abstract.", "study_duration": "DMT was administered 15 minutes before a 60-minute ischemia period, followed by 120 minutes of reperfusion.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:30.858947+00:00"}
{"study_id": 29305, "supplement_id": 1366, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to assess the sub-acute and long-term effects of inhaling vapor from dried toad secretion containing 5-MeO-DMT on affect and cognition, and whether these changes were associated with the psychedelic experience.", "results_summary": "The study found significant increases in satisfaction with life and convergent thinking immediately after intake, maintained at 4 weeks, along with increased mindfulness and reduced depression, anxiety, and stress. Higher levels of ego dissolution or oceanic boundlessness correlated with greater improvements in well-being.", "population_specificity": "42 individuals who inhaled vapor from dried toad secretion at several European locations.", "effective_dosage": "Not specified", "study_duration": "Single inhalation, with follow-up assessments at 24 hours and 4 weeks.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:31.700105+00:00"}
{"study_id": 29307, "supplement_id": 1366, "safety_score": "30", "efficacy_score": 50, "quality_score": 20, "study_goal": "The researchers examined the effects of chronic DMT use, augmented with phenelzine, in a physician self-medicating refractory bipolar depression, focusing on its psychoactive and therapeutic potential.", "results_summary": "The study reported adverse mental health effects, including mania and psychosis, linked to chronic DMT use, while also discussing its theorized mechanisms in depression treatment via serotonin receptor activity.", "population_specificity": "A single physician with refractory bipolar depression.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "Phenelzine (a monoamine oxidase inhibitor) was used alongside DMT.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:34.300668+00:00"}
{"study_id": 29308, "supplement_id": 1366, "safety_score": "70", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to review the current literature on DMT's recreational use, its potential roles as an endogenous neurotransmitter, and its pharmacokinetics, mechanisms of action, clinical uses, and adverse effects.", "results_summary": "The study found that DMT produces intense psychedelic effects, has limited neurotoxicity, and may play roles in nervous system signaling. It suggests potential clinical utility for anxiety and psychosis but notes intense cardiovascular effects at high intravenous doses.", "population_specificity": "Not specified (literature review)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:34.695005+00:00"}
{"study_id": 29309, "supplement_id": 1366, "safety_score": "20", "efficacy_score": 50, "quality_score": 30, "study_goal": "The researchers aimed to document a case of substance-induced psychosis attributable to repeated N,N-Dimethyltryptamine (DMT) use and its treatment outcomes.", "results_summary": "The study found that repeated DMT use led to substance-induced psychosis in a patient with no prior psychiatric history, which resolved with antipsychotic treatment. The patient remained symptom-free and drug-free six months post-treatment.", "population_specificity": "A 42-year-old white man with no significant past psychiatric history.", "effective_dosage": "Not specified", "study_duration": "3 weeks of treatment", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:35.145688+00:00"}
{"study_id": 29310, "supplement_id": 1366, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine the immunomodulatory effects of N,N-Dimethyltryptamine (NN-DMT) on human monocyte-derived dendritic cells (moDCs) via the sigma-1 receptor.", "results_summary": "NN-DMT inhibited pro-inflammatory cytokine production (IL-1\u03b2, IL-6, TNF\u03b1, IL-8) and increased anti-inflammatory IL-10 secretion in moDCs. It also reduced Th1 and Th17 inflammatory T-cell differentiation in a sigma-1 receptor-dependent manner.", "population_specificity": "Human primary monocyte-derived dendritic cells (moDCs) stimulated with LPS, polyI:C, or pathogen-derived stimuli.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:37.485930+00:00"}
{"study_id": 29312, "supplement_id": 1366, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to develop and demonstrate a method for analyzing DMT and 5-methoxy DMT in rat brain tissue using solid-phase extraction and LC-APcI-MS-MS-ID.", "results_summary": "The study successfully developed a method for extracting and analyzing DMT and 5-methoxy DMT in rat brain tissue, demonstrating its applicability by administering the compounds intraperitoneally and analyzing brain regions post-treatment.", "population_specificity": "Rats", "effective_dosage": "5 mg/kg (single dose)", "study_duration": "15 minutes post-treatment", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:37.951031+00:00"}
{"study_id": 29311, "supplement_id": 1366, "safety_score": "30", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate the pharmacokinetic properties of 5-MeO-DMT in mice, focusing on dose-dependent nonlinearity and the role of CYP2D6 metabolism.", "results_summary": "The study found that systemic exposure to 5-MeO-DMT increased nonproportionally with higher doses, indicating nonlinear pharmacokinetics. Brain concentrations of 5-MeO-DMT also rose disproportionately with dose, suggesting heightened intoxication risk at higher doses.", "population_specificity": "CYP2D6-humanized (Tg-CYP2D6) and wild-type mice.", "effective_dosage": "2, 10, and 20 mg/kg (intravenous or intraperitoneal).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:39.123612+00:00"}
{"study_id": 29314, "supplement_id": 1366, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the influence of gangliosides (GANG) on stress-induced behavioral and physiological changes in rats, particularly in response to 5-MeO-DMT.", "results_summary": "The study found that GANG combined with repeated stress enhanced certain behavioral responses to 5-MeO-DMT (e.g., forepaw treading, hindlimb abduction) and reversed stress-induced reductions in motor activity and body weight loss.", "population_specificity": "Rats subjected to restraint stress.", "effective_dosage": "5-MeO-DMT (5 mg/kg, IP); GANG (30 mg/kg, IP).", "study_duration": "3 consecutive days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:41.066598+00:00"}
{"study_id": 29313, "supplement_id": 1366, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to investigate the dose-response effects of DMT, assess tolerance development, and explore the role of the 5-HT1A receptor in mediating its psychological effects.", "results_summary": "DMT showed no tolerance to psychological effects despite repeated dosing, while biological responses were inconsistently reduced. Pindolol pre-treatment enhanced psychological responses, suggesting 5-HT1A agonism modulates 5-HT2-mediated psychedelic effects.", "population_specificity": "Experienced hallucinogen users", "effective_dosage": "Four closely spaced hallucinogenic doses (specific amounts not stated)", "study_duration": "Not specified", "interactions": "Pindolol increased psychological responses to DMT", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:41.157618+00:00"}
{"study_id": 29315, "supplement_id": 1366, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine how acute and chronic treatment with serotonin uptake inhibitors (zimelidine, alaproclate, chlorimipramine) affects nociception and response to 5-MeO-DMT in mice.", "results_summary": "Acute treatment with serotonin uptake inhibitors produced antinociception in the hot-plate test but not the tail-flick test. Chronic treatment led to reduced tail-flick latencies and increased response to 5-MeO-DMT in the tail-flick test, suggesting supersensitivity of spinal 5-HT receptors.", "population_specificity": "Mice", "effective_dosage": "Not specified", "study_duration": "Chronic treatment duration not specified (effects assessed up to 144 hours post-withdrawal)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:44.528700+00:00"}
{"study_id": 29316, "supplement_id": 1366, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the role of noradrenaline (NA) in modulating the antinociceptive effects of 5-MeODMT, a derivative of N,N-Dimethyltryptamine, in nociception tests.", "results_summary": "The study found that 5-MeODMT's antinociceptive effects were abolished by NA depletion but restored by NA administration, highlighting NA's necessity for 5-MeODMT-induced analgesia. Intrathecal 5,7-DHT attenuated these effects, indicating serotonergic involvement.", "population_specificity": "Animal model (specific species not mentioned in abstract).", "effective_dosage": "1 mg/kg (subcutaneous) for 5-MeODMT; 1-2 micrograms (intrathecal) for NA.", "study_duration": "Acute administration (single dose).", "interactions": "Interaction with noradrenaline and serotonergic systems noted.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:45.557286+00:00"}
{"study_id": 29317, "supplement_id": 1366, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to determine how chronic and acute treatment with various antidepressant drugs, including desipramine and amitriptyline, affected pain thresholds in rats treated with saline or 5-MeODMT (a compound related to N,N-Dimethyltryptamine).", "results_summary": "Chronic desipramine treatment attenuated 5-MeODMT-induced analgesia in multiple nociception tests, while chronic amitriptyline potentiated it in some tests. Acute treatment with antidepressants elevated shock thresholds in saline-treated rats, but effects differed between chronic and acute administration.", "population_specificity": "Rats (saline- and 5-MeODMT-treated)", "effective_dosage": "1 mg/kg (5-MeODMT)", "study_duration": "Chronic treatment duration not specified", "interactions": "Antidepressants (desipramine, amitriptyline, iprindole, alaproclate, zimeldine, mianserin) showed varying interactions with 5-MeODMT effects.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:46.687199+00:00"}
{"study_id": 29318, "supplement_id": 1366, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to study the effects of 5-MeO-DMT and MAO inhibitors on ejaculatory response and 5-HT behavioral syndrome in rats.", "results_summary": "Repeated treatment with 5-MeO-DMT strongly reduced ejaculatory and behavioral responses, while MAO inhibitors showed varied effects, with combined MAO-A inhibition and 5-HT release producing the strongest blockade.", "population_specificity": "Rats", "effective_dosage": "3 mg kg-1, i.p.", "study_duration": "Repeated treatment (specific duration not stated)", "interactions": "Combined treatment with clorgyline plus PCA caused near-complete blockade of responses.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:47.094614+00:00"}
{"study_id": 29320, "supplement_id": 1366, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to investigate the effects of repeated administration of tryptaminergic drugs, including 5-MeO-DMT, on postdecapitation convulsions (PDCs) and 5-HT receptor sensitivity changes at the spinal level.", "results_summary": "Repeated administration of tryptaminergic drugs, including 5-MeO-DMT, blocked the acute effects of 5-MeO-DMT on PDCs, suggesting down-regulation of 5-HT receptors mediating these effects. The study provides a model for studying 5-HT receptor sensitivity changes.", "population_specificity": "Not specified (likely animal model based on methodology).", "effective_dosage": "5-MeO-DMT (3 X 2 mg kg-1), acute doses (2 and 4 mg kg-1).", "study_duration": "10 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:49.121450+00:00"}
{"study_id": 29319, "supplement_id": 1366, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate the effects of acute and repeated treatment with selective 5-HT uptake inhibitors on the ejaculatory response and 5-HT behavioral syndrome induced by 5-MeODMT in rats.", "results_summary": "Acute doses of fluoxetine and zimeldine reduced the ejaculatory response, which was prevented by methergoline. Repeated fluoxetine treatment prolonged the blockade and delayed sensitization. Alaproclate and citalopram blocked the response at 1 hour but had no other effects.", "population_specificity": "Rats", "effective_dosage": "5-MeODMT (3 mg kg-1 i.p.), oral doses of fluoxetine, zimeldine, alaproclate, and citalopram based on ED50 values", "study_duration": "Acute doses (48 h, 7, 14, 24 days), repeated treatment (5 times over 9 days, 10 times over 19 days)", "interactions": "Interaction with 5-HT uptake inhibitors (fluoxetine, zimeldine, alaproclate, citalopram) and 5-HT receptor antagonist (methergoline)", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:49.594782+00:00"}
{"study_id": 77147, "supplement_id": 1401, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate disruptions in postprandial lipid metabolism and triglyceride-rich lipoprotein composition in obese adolescents.", "results_summary": "The abstract does not provide specific results regarding Orange Juice's effects.", "population_specificity": "Obese adolescents aged 12 to 16 years (BMI > 30 kg/m\u00b2).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:56.895616+00:00"}
{"study_id": 77145, "supplement_id": 1401, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to systematically review the influence of dietary interventions, including food and beverages, on the bioavailability of quinolones.", "results_summary": "The study found that 74% of quinolones with available food impact data had potentially clinically important interactions, but Orange Juice was not specifically mentioned in the abstract.", "population_specificity": "Not specified (general focus on quinolone pharmacokinetics)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned (Orange Juice not specifically addressed)", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:57.728652+00:00"}
{"study_id": 28213, "supplement_id": 1401, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to determine the immune response induced by orange juice or hesperidin on macrophages, focusing on cytokine secretion and nitric oxide levels.", "results_summary": "Orange juice increased IL-12 levels in non-LPS-stimulated macrophages and decreased TNF-alpha secretion in LPS-stimulated macrophages while increasing nitric oxide levels. Hesperidin showed a suppressive effect on inflammation by reducing NO and cytokine levels.", "population_specificity": "Mice", "effective_dosage": "Not specified", "study_duration": "2 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:57.749125+00:00"}
{"study_id": 28211, "supplement_id": 1401, "safety_score": "90", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to compare the effects of commercial and fresh orange juice on endothelial function and physiological characteristics in healthy humans.", "results_summary": "Both commercial and fresh orange juice reduced inflammatory markers (VCAM, hs-CRP, E-selectin) and increased apo A-1 levels, with fresh orange juice also lowering LDL. No significant differences were found between the two juice types except for apo A-1 increases.", "population_specificity": "22 healthy volunteers", "effective_dosage": "Not specified", "study_duration": "4 weeks per juice type (8 weeks total)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:54:58.288578+00:00"}
